•
 
•
 
•
 
•
 
–
 
 
Version 
3
.
0
 
April 
20
, 2020
 
 
VACCINE RESEARCH CEN
TER
 
 
Protocol VRC 
3
2
1
 
(NIH 
19
-
I
-
0032
)
 
 
A
 
P
HASE 
I
 
O
PEN
-
L
ABEL 
C
LINICAL 
T
RIAL TO 
E
VALUATE 
D
OSE
,
 
S
AFETY
,
 
T
OLERABILITY
,
 
AND 
I
MMUNOGENICITY OF AN 
I
NFLUENZA 
H
1
 
S
TABILIZED 
S
TEM
 
F
ERRITIN 
V
ACCINE
,
 
VRC
-
FLUNPF099
-
00
-
VP,
 
I
N 
H
EALTHY 
A
DULTS
 
 
Vaccine Provided by
 
National Institute of Allergy and Infectious Diseases (NIAID)
 
Vaccine
 
Research Center (VRC)
 
Bethesda, Maryland 
 
 
Clinical Trial Sponsored by:
 
National Institute of Allergy and Infectious Diseases (NIAID)
 
Vaccine Research Center (VRC)
 
Bethesda, Maryland
 
BB
-
IND 
18764
 
–
 
held by VRC, NIAID, NIH
 
 
Principal 
Investigator:
 
Alicia Widge, M.D., M.S.
 
 
 
VRC/
NIAID
/
NIH
 
Bethesda, MD 20892
 
 
IRB Initial Review Date: 
August 6, 2018
 
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
2
 
of 
54
 
 
TABLE OF CONTENTS
 
TABLE OF 
ABBREVIATIONS
 
................................
................................
................................
...................
 
6
 
PRÉCIS
 
................................
................................
................................
................................
...........................
 
8
 
 
INTRODUCTION AND RAT
IONALE
 
................................
................................
........................
 
10
 
 
BACKGROUND
 
................................
................................
................................
...........................
 
10
 
 
Rationale For 
Development Of Influenza H1ssF_3928 Vaccine, VRC
-
FLUNPF099
-
00
-
VP
 
.......
 
11
 
 
Human Experience with VRC
-
FLUNPF099
-
00
-
VP vaccine
 
................................
........................
 
12
 
1.3.1
 
Previous Human Experience with HA Ferritin vaccine (HA
-
F A/Sing)
 
...........................
 
12
 
 
Rationale for Study Product Dose
 
................................
................................
................................
..
 
13
 
 
Rationale For 
Study Population
 
................................
................................
................................
.....
 
13
 
 
Assessment Of Vaccine Immunogenicity
 
................................
................................
......................
 
13
 
 
STUDY PRODUCTS
 
................................
................................
................................
......................
 
13
 
 
VRC
-
FLUNPF099
-
00
-
VP
 
................................
................................
................................
.............
 
13
 
 
VRC
-
PBSPLA043
-
00
-
VP, phosphate buffered saline (Diluent)
 
................................
...................
 
14
 
 
Preclinical Studies with VRC
-
FLUNPF099
-
00
-
VP
 
................................
................................
......
 
14
 
 
STUDY OBJECTIVES
 
................................
................................
................................
...................
 
14
 
 
Primary Objectives
................................
................................
................................
.........................
 
14
 
 
Secondary Objectives
................................
................................
................................
.....................
 
14
 
 
Exploratory Objectives
 
................................
................................
................................
..................
 
14
 
 
STU
DY DESIGN AND CLINIC
AL PROCEDURES
 
................................
................................
..
 
14
 
 
Study Population
 
................................
................................
................................
............................
 
15
 
4.1.1
 
Inclus
ion Criteria
 
................................
................................
................................
..............
 
15
 
4.1.2
 
Exclusion Criteria
 
................................
................................
................................
.............
 
16
 
 
Clinical Procedures and Evaluations
................................
................................
..............................
 
17
 
4.2.1
 
Screening
 
................................
................................
................................
..........................
 
17
 
4.2.2
 
Study Schedule
 
................................
................................
................................
..................
 
18
 
4.2.3
 
Enrollment
 
................................
................................
................................
........................
 
18
 
4.2.4
 
Acceptable
 
and Effective Methods of Birth Control
 
................................
.........................
 
18
 
4.2.5
 
Vaccine Administration
 
................................
................................
................................
.....
 
18
 
4.2.6
 
7
-
Day Solicited Reactogenicity and Follow
-
up
 
................................
................................
 
19
 
4.2.7
 
Follow
-
Up through End of Study
 
................................
................................
......................
 
19
 
4.2.8
 
Mucosal Sample Collection
 
................................
................................
..............................
 
20
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
3
 
of 
54
 
4.2.9
 
Blood Sample Collection
 
................................
................................
................................
..
 
20
 
4.2.
10
 
Apheresis
 
................................
................................
................................
...........................
 
20
 
4.2.11
 
Apheresis Eligibility Criteria
 
................................
................................
............................
 
21
 
4.2.12
 
Concomitant Medications
 
................................
................................
................................
.
 
21
 
 
Criteria for Dose Escalation and Dose Continuation
 
................................
................................
.....
 
21
 
 
Criteria for Discontinuing Study Injections or Protocol Participation
 
................................
...........
 
22
 
4.4.1
 
Discontinuation of Study Injections
 
................................
................................
..................
 
22
 
4.4.2
 
Discontinuation from Protocol Participation
 
................................
................................
...
 
23
 
 
Criteria for Pausing and Resuming the Study
 
................................
................................
................
 
23
 
4.5.1
 
Plan for Pausing the Study
 
................................
................................
...............................
 
23
 
4.5.2
 
Plan for Review of Pauses and Resuming the Study
 
................................
.........................
 
23
 
 
SAFETY AND ADVERSE E
VENT REPORTING
 
................................
................................
.....
 
24
 
 
Adverse Events
 
................................
................................
................................
..............................
 
24
 
 
Serious Adverse Events
 
................................
................................
................................
.................
 
24
 
 
Adverse Event Reporting to the IND Sponsor
 
................................
................................
...............
 
25
 
5.3.1
 
IND Sponsor Reporting to the FDA
 
................................
................................
..................
 
25
 
 
Reporting to the Institutional Review Board
 
................................
................................
.................
 
26
 
5.4.1
 
Unanticipated Problem
 
................................
................................
................................
.....
 
26
 
5.4.2
 
Protocol Deviation
 
................................
................................
................................
............
 
26
 
5.4.3
 
Non
-
Compliance
 
................................
................................
................................
...............
 
27
 
5.4.4
 
Death
 
................................
................................
................................
................................
.
 
27
 
5.4.5
 
New Information
 
................................
................................
................................
...............
 
27
 
5.4.6
 
Suspension or Termination of Research Activities
 
................................
...........................
 
28
 
5.4.7
 
Expedited Reporting to the IRB
 
................................
................................
........................
 
28
 
5.4.8
 
Annual Reporting to the IRB
 
................................
................................
.............................
 
28
 
 
STATISTICAL CONSIDER
ATIONS
 
................................
................................
..........................
 
28
 
 
Overview
 
................................
................................
................................
................................
........
 
28
 
 
Endpoints
 
................................
................................
................................
................................
.......
 
28
 
6.2.1
 
Primary Endpoints: Safety
 
................................
................................
................................
 
28
 
6.2.2
 
Secondary Endpoints: Immunogenicity
 
................................
................................
............
 
29
 
6.2.3
 
Exploratory Endpoints: Immunogenicity
 
................................
................................
..........
 
29
 
 
Sample Size and Accrual
 
................................
................................
................................
...............
 
29
 
6.3.1
 
Power Calculations for Safety
 
................................
................................
..........................
 
29
 
6.3.2
 
Power Calculations for Immunogenicity
 
................................
................................
..........
 
31
 
6.3.3
 
Power for Comparison
 
................................
................................
................................
......
 
31
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
4
 
of 
54
 
 
Statistical Analysis
 
................................
................................
................................
.........................
 
31
 
6.4.1
 
Analysis Variables
 
................................
................................
................................
............
 
31
 
6.4.2
 
Baseline Demographics
 
................................
................................
................................
....
 
31
 
6.4.3
 
Safety Analysis
 
................................
................................
................................
..................
 
31
 
6.4.4
 
Immunogenicity Analysis
 
................................
................................
................................
..
 
32
 
6.4.5
 
Missing Data
 
................................
................................
................................
.....................
 
32
 
6.4.6
 
Interim Analyses
 
................................
................................
................................
...............
 
32
 
 
PHARMACY AND VACCINE
 
ADMINISTRATION PROC
EDURES
 
................................
....
 
33
 
 
Study Product
 
................................
................................
................................
................................
.
 
33
 
 
Study Product Presentation and Storage
 
................................
................................
........................
 
33
 
7.2.1
 
Study Product Labels
 
................................
................................
................................
........
 
33
 
7.2.2
 
Study Product Storage
 
................................
................................
................................
......
 
33
 
7.2.3
 
Temperature excursions
 
................................
................................
................................
....
 
34
 
 
Preparation of
 
Study Products for Injection
 
................................
................................
...................
 
34
 
7.3.1
 
Preparation of VRC
-
FLUNPF099
-
00
-
VP for Needle and Syringe Administration
 
..........
 
34
 
7.3.2
 
Administration of Injections
 
................................
................................
..............................
 
34
 
 
Study Product Accountability
 
................................
................................
................................
........
 
34
 
7.4.1
 
Documentation
 
................................
................................
................................
..................
 
34
 
7.4.2
 
Disposition
 
................................
................................
................................
........................
 
35
 
 
HUMAN SUBJECT PROTEC
TIONS AND ETHICAL OB
LIGATIONS
 
................................
 
35
 
 
Institutional Review Board
 
................................
................................
................................
............
 
35
 
 
Subject Identification and Enrollment of Study Participants
 
................................
.........................
 
35
 
8.2.1
 
Participation of Children
 
................................
................................
................................
..
 
35
 
8.2.2
 
Participation of NIH 
Employees
 
................................
................................
.......................
 
35
 
 
Informed Consent
 
................................
................................
................................
..........................
 
36
 
 
Subject Confidentiality
 
................................
................................
................................
..................
 
36
 
 
Risks and Benefits
 
................................
................................
................................
.........................
 
36
 
8.5.1
 
Risks of the VRC
-
FLUNPF099
-
00
-
VP vaccine
 
................................
................................
 
36
 
8.5.2
 
Risks of Specimen Collections
 
................................
................................
..........................
 
37
 
8.5.3
 
Risks of study vaccines on the fetus or nursing infant
 
................................
......................
 
37
 
8.5.4
 
Risks of New Diagnoses
 
................................
................................
................................
....
 
37
 
8.5.5
 
Study Benefits
 
................................
................................
................................
....................
 
37
 
 
Plan for Use and Storage of Biological Samples
 
................................
................................
...........
 
38
 
8.6.1
 
Use of Samples, Specimens and Data
 
................................
................................
...............
 
38
 
8.6.2
 
Storage and Tracking of Blood Samples and Other Specimens
 
................................
........
 
38
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
5
 
of 
54
 
8.6.3
 
Disposition of Samples, Specimens and Data at Completion of the Protocol
 
..................
 
38
 
8.6.4
 
Loss or Destruction of Samples, Specimens or Data
 
................................
........................
 
39
 
 
Compensation
 
................................
................................
................................
................................
 
39
 
 
Safety Monitoring
 
................................
................................
................................
..........................
 
39
 
8.8.1
 
Protocol Safety Review Team
 
................................
................................
...........................
 
39
 
 
ADMINISTRATIVE AND L
EGAL OBLIGATIONS
 
................................
................................
.
 
40
 
 
Protocol Amendments and Study Termination
 
................................
................................
..............
 
40
 
 
Study Documentation and Storage
 
................................
................................
................................
.
 
40
 
 
Data Collection, Data Sharing and Protocol 
Monitoring
 
................................
...............................
 
40
 
9.3.1
 
Data Collection
 
................................
................................
................................
.................
 
40
 
9.3.2
 
Data Sharing Plan
 
................................
................................
................................
............
 
41
 
9.3.3
 
Source Documents
 
................................
................................
................................
............
 
41
 
9.3.4
 
Protocol Monitoring Plan
 
................................
................................
................................
.
 
41
 
 
Language
 
................................
................................
................................
................................
........
 
41
 
 
Policy Regarding Research
-
Related Injuries
 
................................
................................
.................
 
41
 
 
REFERENCES
 
................................
................................
................................
................................
 
42
 
APPENDIX I: SCHEDULE
 
OF EVALUATIONS
 
................................
................................
...................
 
44
 
APPENDIX II: ASSESSM
ENT OF RELATIONSHIP 
TO VACCINE AND GRADI
NG SEVERITY 
OF ADVERSE EVENTS
 
................................
................................
................................
.............................
 
47
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
6
 
of 
54
 
TABLE OF ABBREVIATIO
NS
 
Abbreviation
 
Term
 
AE
 
adverse event
 
AdEDC
 
Advantage Electronic Data Capture
 
ALP
 
alkaline phosphatase
 
ALT
 
alanine aminotransferase
 
AoU
 
assessment of understanding
 
BMI
 
body mass index
 
CBC
 
complete blood count
 
CDC
 
Centers for Disease Control and Prevention
 
cGMP
 
current Good Manufacturing Practices
 
dbGAP
 
Database of Genotypes and Phenotypes
 
DNA
 
deoxyribonucleic acid
 
DTM
 
Department of Transfusion 
Medicine
 
FDA
 
Food and Drug Administration
 
GCP
 
Good Clinical Practices
 
GLP
 
Good Laboratory Practices
 
HA
 
influenza hemagglutinin protein 
 
HIV
 
human immunodeficiency virus
 
HLA
 
human leukocyte antigen
 
HRPP
 
Human Research Protection Program
 
IB
 
Investigator’s Brochure
 
ICS
 
intracellular cytokine staining
 
ILI
 
influenza
-
like illness 
 
IM
 
Intramuscular
 
IND
 
investigational new drug application
 
IRB
 
Institutional Review Board
 
IUD
 
intrauterine device
 
LIMS
 
Laboratory Information Management System
 
MedDRA
 
Medical Dictionary for Regulatory Activities
 
MIV
 
Monovalent Inactivated Vaccine
 
M
PA
 
Medroxyprogesterone acetate
 
MSD
 
meso
-
scale delivery
 
NA
 
neuraminidase 
 
NAb
 
Neutralizing antibody
 
NIAID
 
National Institute of Allergy and Infectious Diseases
 
NIH
 
National Institutes of Health
 
NIH CC
 
NIH Clinical Center
 
NSAID
 
nonsteroidal 
anti
-
inflammatory drug
 
PBMC
 
peripheral blood mononuclear cells
 
PCR
 
polymerase chain reaction
 
PI
 
Principal Investigator
 
PSRT
 
Protocol Safety Review Team
 
RBS
 
receptor binding site
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
7
 
of 
54
 
Abbreviation
 
Term
 
RNA
 
ribonucleic acid
 
SAE
 
serious adverse event
 
SARS
 
Severe acute 
respiratory syndrome
 
SUSAR
 
serious and unexpected suspected adverse reaction
 
TNF
 
tumor necrosis factors
 
TIV
 
trivalent inactivated vaccine
 
ULN
 
upper
 
limit of normal
 
UP
 
Unanticipated Problem
 
VCMP
 
Vaccine Clinical Materials Program
 
 
VIP
 
Vaccine Immunology 
Program 
 
VRC
 
Vaccine Research Center
 
WBC
 
white blood cell
 
WHO
 
World Health Organization
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
8
 
of 
54
 
PR
É
CIS
 
 
Title
:
 
VRC 321, 
A Phase I 
Open
-
Label 
Clinical Trial to Evaluate the Dose, Safety, Tolerability 
and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine,
 
 
                          
VRC
-
FLUNPF099
-
00
-
VP, in Healthy Adults
 
Study 
 
Design:
 
Thi
s is a 
P
hase I, open
-
label, 
dose escalation study 
to evaluate the dose, safety, 
tolerability, and immunogenicity of VRC
-
FLUNPF099
-
00
-
VP
 
in two regimens
.
 
The 
hypotheses are that the vaccine is safe and tolerable and will elicit an immune response. 
The prima
ry objective is to evaluate the safety and tolerability of the investigational 
vaccine in healthy adults. Secondary objectives are related to immunogenicity of the 
investigational vaccine and dosing regimen.
 
Study 
 
Products:       
 
The 
investigational vaccine, VRC
-
FLUNPF099
-
00
-
VP
 
(H1ssF_3928)
, was developed by 
the 
Vaccine Research Center (
VRC
)
, 
National Institute of Allergy and Infectious 
Diseases (
NIAID
)
 
and
 
is composed of 
Helicobacter pylori 
non
-
heme ferritin assembled 
with influenza v
irus H1
 
haemagglutinin (HA)
 
insert to form a nanoparticle displaying
 
eight HA
 
stabilized stem
 
trimer
s
 
from A/New Caledonia/20/1999 (H1N1) influenza
. The 
vaccine is supplied in single
-
use vials at a concentration of 180 
mcg
/mL.
 
H1ssF_3928
 
will be administer
ed intramuscularly (IM) in the deltoid muscle
 
via needle and syringe.
 
Subjects:
 
H
ealthy adults 
between the 
ages
 
of
 
18
-
70 years
,
 
inclusive
.
 
Study Plan
:    
 
The study
 
will evaluate the safety, tolerability and immunogenicity of 1 or 2 doses of the 
H1ssF_3928 vaccine in a dose
-
escalation design. In Group 1, five subjects will receive a
 
single
 
low dose 
(
20 
mcg)
 
of H1ssF_3928
 
on Day 0. 
For Group 1, the protocol requires 1 
vaccination visit, 
about 
9
 
follow
-
up
 
visits, and 
a 
telephone contact after 
vaccination
. 
 
 
If 
the
 
low dose is assessed as safe and well tolerated,
 
enrollment will begin for Group 2
A
. 
Groups 2A, 2B, 2C, and 2D 
are
 
stratified by age as shown in the vaccination schema. In 
Group 2A, subjects will receive 
a
 
higher dose (60 mcg) of H1ssF_3928 on Day 0
.
 
I
f this 
higher dose is assessed as safe 
and well tolerated
,
 
subjects in Group 2A 
may
 
recei
ve a 
second vaccination at week 16 and enrollment can begin for 
Groups 2B, 2C, and 2D
.
 
 
For 
Group
s
 
2
A
, 
2
B, 
2C
, and 
2
D
, the protocol requires 
2 vaccination visits, 
about 
1
1
 
follow
-
up
 
visits, and 
a
 
telephone contact after 
each vaccination
. 
 
For all 
g
roups
, solicited reactogenicity will be evaluated using a 7
-
day diary card. 
Assessment of vaccine safety will include clinical observation and monitoring of 
hematological and chemical parameters at clinical visits throughout the study.
 
 
VRC 321 
Vaccination Schema
 
Group
 
Age Cohort
 
Subjects
 
Day 0
 
Week 16
 
1
 
18
-
40
 
5
 
20
 
mcg
 
 
2
A
 
18
-
40
 
1
2
 
60
 
mcg
 
60
 
mcg
 
2
B
 
41
-
49
 
1
2
 
60
 
mcg
 
60
 
mcg
 
2
C
 
50
-
59
 
1
2
 
60
 
mcg
 
60
 
mcg
 
2
D
 
60
-
70
 
1
2
 
60
 
mcg
 
60
 
mcg
 
Total
 
53
*
 
*Enrollment up to 
7
0
 
is permitted if additional
 
subjects
 
are
 
needed
 
for
 
safety
 
or immunogenicity 
evaluations
.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
9
 
of 
54
 
Study 
 
Duration
: 
 
Group 1
: 
Subjects will be evaluated for 
52
 
weeks
 
following the vaccine administration
 
and through 
an 
influenza season.
 
                       
 
Group
s
 
2
A, 2B, 2C, 2D
: Subjects will be evaluated for 
52
 
weeks following the 
last 
vaccine administration
 
and
 
through 
an 
influenza season.
 
 
 
 
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
10
 
of 
54
 
 
INTRODUCTION AND RAT
IONALE
 
 
BACKGROUND
 
Influenza virus causes seasonal epidemics and pandemics at irregular intervals that result in 
significant morbidity and mortality. According to the World Health Organization
 
(WHO)
, the 
annual global attack rate of influenza is estimated to be 5%
–
10% in adults and 20%
–
30% in 
children; worldwide these annual epidemics result in about 3 to 5 million c
ases of severe illness 
and about 250,000 to 500,000 deaths 
[
1
]
. 
The
 
US Centers for Disease Control and Prevention
 
(CDC)
 
estimates that a pandemic 
i
nfluenza outbreak costs the United States between $71 billion 
and $167 billion without counting the financial impact on commerce and society
 
[
2
]
.
 
Infl
uenza is a
n
 
enveloped, 
negative
 
single
-
stra
nd
ed
 
(
-
ss)
 
ribonucleic acid (RNA) virus 
that 
belongs to the family 
Orthomyxoviridae
. Of the 
five
 
genera of influenza circulating in nature,
 
only 
influenza A and B 
are known to cause epidemics
 
in human
s 
[
3
]
.
 
 
Influenza A viruses 
consist of 8 RNA g
ene 
segments and
 
are 
classified 
based on
 
the antigenicity 
of their surface glycoproteins: hemagglutinin (HA) and neuraminidase (NA). 
There are 18 
different HA subtypes (H1 through H18) and 11 NA subtypes known to exist, but only three HA 
subtypes (H1, 
H
2
, and
 
H3) and two NA subtypes (N1 and N2) have caused significant human 
epidemics
 
[
4
]
.
 
 
The HA is the predominant viral antigen target for antibo
dy neutralization
 
[
5
]
.
 
HA glycoprotein 
consists of a globular head 
domain 
(which is highly variant
 
in structure
 
between HA subtypes)
 
and 
a stem
 
domain
 
(which is 
highly 
conserved across HA subtypes)
 
[
6
]
. 
Most of the antibodies 
produced by the immune system after infection recognize the head domain
, 
whereas the stem 
domain is recognized by 
a
 
small population of antibodies 
[
7
-
9
]
. 
The anti
-
head antibo
dies are 
very 
potent
 
but are strain
-
specific 
while
 
the
 
anti
-
stem
 
antibodies
 
are less potent 
and
 
are cross
-
reactive across 
HA 
strains
 
[
10
]
. 
 
Influenza exhibits genetic flexib
ility and antigenic variability because of its ability to go through 
antigenic “drift” (the gradual accumulation of mutations over time) and antigenic “shift” (the 
replacement of the hemagglutinin gene by reassortment during contemporaneous infection of a 
host by more than one influenza strain)
.
 
T
he emergence of new influenza strains
 
through
 
c
ontinuous mutation
 
and reassortment
 
of circulating virus diminish
es
 
the effectiveness of annual 
influenza 
vaccines
 
[
11
, 
12
]
.
 
F
urthermore, 
in the United 
States
, the
 
current
 
manufacturing process in egg
-
based systems can 
lead to lower yields and significant lag times 
due to 
virus strain identification
 
and
 
vaccine 
production, 
availability, and distribution
 
[
13
, 
14
]
.
 
T
hese 
limitations 
have raised the need 
for
 
developing a universal influenza vaccine that can 
provide durable, cross
-
strain protection against different influenza viruses, with a rapid 
manufacturing process in which large vaccine quantities could be produced under well
-
controlled con
ditions. 
A univ
ersal influenza vaccine would
 
eliminat
e
 
the need for annual 
reformulation and revaccination, and improv
e
 
pandemic preparedness
 
[
15
]
.
 
With
 
the goal of 
developing 
a universal influenza vaccine, 
t
he Vacc
ine Research Center (VRC), 
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health 
(NIH) has 
engineered 
and optimize
d
 
a stabilized H1 influenza HA stem ferritin vaccine 
(
VRC
-
FLUNPF099
-
00
-
VP
) 
that 
enhances the presen
t
ation of
 
the H
A stem
 
to the immune system, 
potentially 
improving breadth against 
group 1 
influenza 
strains
.
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
11
 
of 
54
 
VRC
-
FLUNPF099
-
00
-
VP
 
(
H1ssF_3928) 
is an investiga
tional 
vaccine
 
that has not 
been 
administered
 
to humans 
before
 
this study
. 
The 
H1ssF_3928
 
vaccine 
may inform the development 
of a universal influenza vaccine and 
play
 
an important role in the 
planning and preparation for
 
future influenza pandemics
 
[
16
]
.
 
 
 
R
ATIONALE 
F
OR 
D
EVELOPMENT 
O
F 
I
NFLUENZA
 
H1
SS
F_3928
 
V
ACCINE
,
 
VRC
-
FLUNPF099
-
00
-
VP
 
N
ew vaccine platform
s
 
and production technologies 
directed 
toward the goal of a universal 
influenza vaccine include 
cell
-
culture
-
based manufacturing processes, novel live attenuated 
vaccines, recombinant proteins
,
 
recombinant DNA
-
based vaccines
, and nanoparticles
 
[
13
, 
14
]
.
 
Ferritin is 
a 
highly conserved, 
ubiquitous
 
iron storage protein 
that is
 
found 
in
 
various species 
from Archaea,
 
Eukarya, and Bacteria domains
 
[
17
]
. Ferritin particles
 
can 
be used
 
in vaccines
 
for 
antigen presentation of influenza HA
 
[
18
]
.
 
Ferritin self
-
as
sembles into a nearly
-
spherical 
nanoparticle, composed of 24 subunits organized in an octahedral symmetry with a hollow 
interior, that mimics the structure of the viral antigen and mediates the inte
raction with the 
immune system
 
[
18
, 
19
]
.
 
T
he advantages of 
using 
ferritin 
as a vaccine platform 
to improve
 
antigen presentation and immune stimulation 
against 
different
 
strains of influenza 
viruses
 
r
ely on 
the 
ability to obtain higher levels of protein quaternary structures and the capacity to display 
heterologous 
antigens on their surface
 
[
18
, 
20
]
. 
Furthermore, as 
the 
self
-
assembly
 
process 
requires no energy
 
and can be manufactured from simple expression vectors 
(
without relying on 
egg
-
based systems
)
, 
v
accine manufacturing time
lines 
could
 
be potentially shortened
,
 
improv
ing
 
the response to an
 
influenza 
pandemic
 
[
18
]
.
 
Investigators at the 
VRC, NIAID, NIH, Bethesda, MD
, US,
 
have 
identified 
a non
-
haem 
ferritin
 
from 
Helicobacter pylori
 
(
H. 
pylori) 
as a 
protein 
able to display
 
eight
 
trimeric influenza HA 
spikes that mimic the physiological HA structure 
of 
A/New Caledonia/20/1999 (H1N1) 
influenza
.
 
 
Kanekiyo, 
et 
al
.
 
genetically fused 
the ectodomain of A/New Caledonia/20/1999 
HA to 
H. 
pylori 
ferritin
, creating a 
vaccine 
that 
antigenically resembles the 
native
 
head and stem domains of the 
HA 
viral spikes on the surface of the ferritin spherical core
 
[
18
]
.
 
 
In p
reclinical immunogenicity 
studies
,
 
this HA
 
ferritin 
vaccine
 
elicit
ed
 
two types of broadly neutralizing antibodies against the 
highly conserved HA stem
 
and 
antibodies against 
the conserved receptor binding site (RBS) 
on 
the head 
of the viral HA
. The HA stem and the RBS
 
are structures of major interest for the 
development of
 
a unive
rsal
 
vaccine against influenza
 
[
21
]
.
 
Y
assine, 
et al.
 
genetically fused the ectodomain of A/New Caledonia/20/1999 HA 
that lack
s
 
the 
immunodominant head domain
 
to 
H. pylori 
ferritin, creating a synthetic ferritin that antigenically 
resembles the native stem domain of the HA 
protein
 
on the surface of the ferritin spherical core 
[
16
]
.
 
In preclinical immunogenicity studies, this 
H1 
HA 
stem 
ferritin vaccine 
confer
red
 
heterosubtypic protection
 
against H5N1 influenza virus challenge
 
in multiple animal
 
models
, 
indicating that vaccine
-
elicited HA stem
–
specific antibodies can protect against diverse group 1 
influenza strains
 
[
16
]
.
 
 
Both of these 
HA
 
ferritin
 
vaccine
s
 
posses
s
 
the desired structural 
properties
 
and ha
ve 
demonstrated 
the capacity to enhance the breadth of neutralizing antibodies in pre
-
clinical 
studies
 
when 
compared
 
to the current commercial trivalent inactivated vaccine (TIV) co
ntaining 
the same 1999 H1N1 H
A 
[
18
]
 
[
16
]
. 
Based on data reported with th
e
 
HA
 
stem
 
ferritin 
vaccine 
i
n 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
12
 
of 
54
 
animal studies (
Section
 
2.3
)
, it 
is expected
 
that 
the 
H1ssF_3928 
vaccine
 
will be safe and 
immunogenic in this 
P
hase 
I study in humans. 
 
 
H
UMAN 
E
XPERIENCE WITH 
VRC
-
FLUNPF099
-
00
-
VP
 
VACCINE
 
 
This is the first 
clinical 
study to test the VRC
-
FLUNPF099
-
00
-
VP vaccine, and there is no 
previous human experience with this product. VRC
-
FLUNPF081
-
00
-
VP (HA
-
F A/Sing) was the 
first ferritin
-
based
 
vaccine platform tested in a 
P
hase I clinical trial, therefore human experience 
with HA
-
F A/Sing is provided below.
 
1.3.1
 
Previous Human Experience with 
HA 
Ferritin 
v
accine
 
(HA
-
F A/Sing)
 
T
he first 
P
hase I 
clinical trial 
(VRC 316
;
 
[STUDY_ID_REMOVED]
)
 
using ferritin par
ticles,
 
HA
-
F A/Sing 
f
erritin vaccine 
was open
ed
 
to accrual 
in October 201
7
.
 
The 
HA
-
F A/Sing vaccine is composed 
of 
H. pylori
 
non
-
haem ferritin 
genetically fused to the 
influenza virus H2 HA to form a 
nanoparticle that antigenically resembles the 
native head and stem domains of the HA from 
A/Singapore/1/57 (H2N2) influenza.
 
 
As of 
March 
24, 2019
, 
enrollment 
was 
complete and all 50 subjects 
have received
 
at least 
one 
injection of 
the 
HA
-
F A/Sing 
vaccine
. All injections with
 
the
 
HA
-
F A/Sing vaccine h
ave been 
generally well tolerated. 
 
Maximum local reactogenicity in the 7 days after 
HA
-
F A/Sing 
administration was reported as
 
mild local pain/tenderness by 7 of 47 (14.9 %) subjects. No other solicited local symptoms of 
swelling or redness were reported.
 
N
o moderate or severe local symptoms 
have
 
been reported.  
 
Regarding s
olicited systemic reactogenicity in the 7 days after product administration, 
18 of 47 
(38.3%) subjects who received HA
-
F A/Sing had one or more systemic signs or symptoms, the 
most frequently reported AE was that of mild headache (13/47, 27.7%). Subjects also reported 
mild malaise (10/47, 21.3%), mild myalgia (8/47, 17.0%), moderat
e myalgia (1/47, 2.1%), mild 
chills (2/47, 4.3%), mild nausea (1/47, 2.1) and mild joint pain (2/47, 4.3%). 
 
One
 
subject reported a severe fever that started on Day 4 after the first product administration, 
resolved within 1 day, and coincided with an 
influenza
-
like illness.
 
Overall for the HA
-
F A/Sing vaccine groups, 22 of 47 (46.8%) subjects who received at least one 
administration of the vaccine have had at least one or more unsolicited AE, with maximum 
severity being Grade 1 (mild) for 12 subjects, 
Grade 2 (moderate) for 8 subjects, Grade 3 
(severe) for 1 subject and Grade 4 (life
-
threatening) for 1 subject. 
 
The most frequently reported unsolicited AEs were anaemia (8/47, 17.0%), with a maximum 
severity of Grade 2 for five subjects, and upper respir
atory tract infection (5/47, 10.6%), with a 
maximum severity of Grade 2 for one subject. 
 
A severe AE of viral infection was reported by 
1
 
subject 9 days after the initial study injection. 
The event was assessed as unrelated to study product and resolved w
ith no residual effects three 
days after onset. 
 
As of March 24, 2019, 3 mild AEs were assessed as related to HA
-
F A/Sing vaccine and all 
resolved with no residual effects:  leukocytosis 
(1/47, 2.1%), 
blood alkaline phosphatase 
increased 
(1/47, 2.1%), 
and 
leukopenia 
(1/47, 2.1%)
 
A  life
-
threatening SAE of myocardial infarction was reported by 
1 subject 
at 117 days after the 
HA
-
F A/Sing  study product administration. The event was assessed as unrelated to study 
product and resolved with sequelae
.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
13
 
of 
54
 
 
R
ATIONALE F
OR 
S
TUDY 
P
RODUCT 
D
OSE
 
The 
VRC 316 study results
 
as of March 18,
 
2018 
showed that 
t
wo
 
dose levels 
(20 mcg as a 
single dose and 60 mcg as a repeat dose
 
with a 16
-
week interval
) 
of
 
HA
-
F A/Sing 
were
 
safe and 
well tolerated
. 
I
n this study, 
H1ssF_3928 
will be 
similarly 
evaluated at 20 mcg as a single dose 
and 60 mcg as a repeat dose
 
with a 16
-
week interval. A 16
-
week interval between first and 
second doses is based on previous VRC studies suggesting that this interval may be optimal to 
develo
p an immune response to the vaccine regimen
.
 
 
R
ATIONALE 
F
OR 
S
TUDY 
P
OPULATION 
 
 
To assess safety, tolerability
,
 
and immunogenicity of the 
H1ssF_3928
 
vaccine
, 
s
ubjects 18
-
70 
years of age 
will be enrolled
.
 
In the higher dose group, s
ubjects will be stratified 
by 
age 
into four 
groups
 
(Groups 2A
-
2D)
 
to 
evaluat
e how 
the
 
immune response
s
 
to the 
H1ssF_3928 vaccine
 
vary
 
based on 
age and 
the 
likelihood of exposure to different influenza strains
.
 
 
A
SSESSMENT 
O
F 
V
ACCINE 
I
MMUNOGENICITY
 
 
In this study, specimens to evaluate immunogenicity will be collected at baseline and at specified 
time points. The primary immunogenicity time point is 
two weeks after the
 
first 
vaccination
 
and 
assessed by measuring 
HA stem
-
specific
 
antibo
dy by 
pseudo
-
neutralization
 
assay
. Additional 
assessment of HA stem
-
specific antibody measured by pseudo
-
neutralization assay
 
will be 
conducted on stored samples obtained throughout the study. 
 
Exploratory evaluations will include 
measurements of human fer
ritin antibody
 
and
 
H. pylori
 
ferritin antibody
.
 
Additional exploratory evaluations may include t
he detection of antibody by 
MSD 
(Meso Scale Delivery) 
or neutralization assay
,
 
and 
e
xploratory 
B and 
T cell assays
.
 
 
Research samples for immunogenicity assays will be processed by the Vaccine Immunology 
Program
 
(
VIP
) in Gaithersburg, MD, where many of the immunogenicity assays will also be 
performed. Some immunogenicity assays may be performed by VRC laboratories in Bet
hesda, 
MD,
 
or by
 
approved contract laboratories or research collaborators.
 
Results from this study are expected to provide a foundation for 
development of 
a universal 
influenza vaccine candidate as well as show proof
-
of
-
concept for 
elicitation of antibody 
responses by
 
influenza HA
 
stem 
vaccination.
 
 
STUDY PRODUCTS
 
The s
tudy 
products
 
are
 
manufactured
 
under current Good Manufacturing Practice (cGMP) by the
 
Vaccine Clinical Materials Program 
(V
CM
P) operated under contract by Leidos Biomedical 
Research, Inc., Fr
ederick, MD. 
 
 
VRC
-
FLUNPF099
-
00
-
VP
 
The 
VRC
-
FLUNPF099
-
00
-
VP
 
(
H1ssF_3928
)
 
vaccine 
is 
composed of 
the 
HA 
stem 
domain
 
from 
Influenza 
A/New Caledonia/20/1999
 
(H1N1)
 
genetically fused to 
the 
ferritin protein from 
H. 
pylori
.
 
P
urified 
H1ssF_3928
 
displays eight 
well
-
formed HA 
trimer
s
 
that antigenically resemble 
the native H
1 stem
 
viral spikes. 
 
VRC
-
FLUNPF099
-
00
-
VP is a sterile, aqueous buffered solution.  
Product is 
aseptically filled to 
a volume of 0.7 
± 0.1 
mL into 
3 mL 
single dose vials at 
a 
concentration of 180 
mc
g/mL
. 
 
The 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
14
 
of 
54
 
buffer consists of 20mM 
Sodium Phosphate
, 100mM 
Sodium Chloride
, 5% Sucrose
 
and 0.01% 
PF
-
68
 
at pH 7.2.
 
More details related to vaccine
 
formulation
, preparation, and preclinical studies performed with
 
H1ssF_3928
 
can be foun
d in the Investigator’s Brochure (IB).
 
 
VRC
-
PBSPLA043
-
00
-
VP,
 
PHOSPHATE BUFFERED 
SALINE 
(D
ILUENT
)
 
VRC
-
PBSPLA043
-
00
-
VP 
will be the d
iluent 
for 
H1ssF_3928
 
and
 
consists of sterile phosphate 
buffered saline (PBS) at pH 7.2, aseptically filled 
to
 
1.2 mL in a 3 mL glass vial for single use.
 
 
P
RECLINICAL 
S
TUD
IES WITH
 
VRC
-
FLUNPF099
-
00
-
VP
 
Non
-
clinical immunogenicity studies in mice 
and ferrets 
demonstrated
 
that 
VRC
-
FLUNPF099
-
00
-
VP
 
administered IM 
was
 
immunogenic as detected by 
ELISA and 
neutralization assay.
  
A 
dose toxicity study 
of 
VRC
-
FLUNPF099
-
00
-
VP
 
was performed in New Zealand white ra
bbits 
to 
evaluate safety.  
More details 
on 
this study and additional 
pre
-
clinical studies with 
VRC
-
FLUNPF099
-
00
-
VP
 
can be found in the IB.  
 
 
STUDY OBJECTIVES
 
 
P
RIMARY 
O
BJECTIVE
S
 
•
 
To evaluate the safety and tolerability of
 
the
 
VRC
-
FLUNPF099
-
00
-
VP
 
vaccine
,
 
administered as a single dose at 20 mcg IM via needle and syringe 
on
 
Day 0 
to healthy 
adults.
 
 
•
 
To evaluate the safety and tolerability of
 
the
 
VRC
-
FLUNPF099
-
00
-
VP 
vaccine, 
administered at 60 mcg IM via needle and syringe to heal
thy adults by repeat dosing 
on
 
Day 0 and 
Week 16 for a total of 2 injections.
 
 
S
ECONDARY 
O
BJECTIVES
 
•
 
To evaluate the antibody response 
to the 
VRC
-
FLUNPF099
-
00
-
VP vaccine 
administered 
as a single dose 
at 20 mcg 
IM via needle and syringe 
a
t 
two
 
weeks 
after inj
ection
.
 
 
•
 
To evaluate the antibody response 
to the
 
VRC
-
FLUNPF099
-
00
-
VP vaccine administered 
as repeat dosing 
at 60 mcg 
IM via needle and syringe at 
two
 
weeks after
 
each 
injection
.
 
 
E
XPLORATORY 
O
BJECTIVES
 
•
 
To evaluate the specificity and 
functionality of vaccine
-
induced antibodies
 
and 
the 
immune response
 
at 
various
 
timepoints 
throughout the study
.
 
 
•
 
To evaluate the 
frequency, 
magnitude
, 
and 
specificity 
of
 
B
-
cell and/or 
T
-
cell responses 
at 
various
 
time points
 
throughout 
the 
study.
 
 
STUDY 
DESIGN AND CLINICAL 
PROCEDURES
 
This is
 
a 
P
hase 
I,
 
open
-
label
, 
dose
 
escalation
 
study to evaluate the dose, safety, tolerability, and 
immunogenicity of 
the 
VRC
-
FLUNPF099
-
00
-
VP
 
vaccine
 
in two dose
 
regimens
 
in healthy 
adults. 
The study schema 
is shown
 
in 
Table 
1
.
 
The hypotheses are that 
the
 
vaccine 
is 
safe, well
-
tolerated, and will induce an antibody response to 
the stem of 
influenza virus subtype H
1
. The 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
15
 
of 
54
 
study will 
be conducted
 
by the VRC Clinical Trials Program at a single site 
in 
the NIH Clinical 
Center
 
(NIH CC)
, Bethesda, MD
.
 
Table 
1
: 
Study schema:
 
VRC 321 Vaccination Schema
 
Group
 
Age 
 
Subjects
 
Day 0 
 
Week 16 
 
 
1
 
18
-
40
 
5
 
20 
mcg
 
 
2A
 
18
-
40
 
1
2
 
60 mcg
 
60 mcg
 
2B
 
41
-
49
 
1
2
 
60 mcg
 
60 mcg
 
2C
 
50
-
59
 
1
2
 
60 mcg
 
60 mcg
 
2D
 
60
-
70
 
1
2
 
60 mcg
 
60 mcg
 
Total
 
5
3
*
 
*Enrollment up to 
7
0
 
is permitted if additional
 
subjects
 
are
 
needed
 
for
 
safety
 
or immunogenicity 
evaluations
.
 
 
S
TUDY 
P
OPULATION
 
All inclusion and exclusion criteria must 
be 
evaluated
 
for eligibility.
 
4.1.1
 
Inclusion Criteria
 
A 
s
u
bj
e
ct
 
must meet all of the following criteria
:
 
1.
 
Healthy adults between the ages of 18
-
70 years inclusive
 
 
2.
 
Based on history and examination, in good general health and without history of any of 
the conditions l
isted in the exclusion criteria
 
3.
 
Received a
t least one
 
licensed 
influenza vaccine
 
from 2014 to the present
 
4.
 
Able and willing to comple
te the informed consent process
 
5.
 
If enrolled in Group 1
: 
Available for clinic visits for 
52
 
weeks
 
after enrollment
 
and 
through
 
an
 
influenza season
 
6.
 
If enrolled in Group 2
A, 2B, 
2C,
 
or 
2D
: Available for clinic visits for 68 weeks after 
enrollment
 
and through 
an
 
influenza season
 
7.
 
Willing to have blood samples collected, stored indefinitely, and used 
for research 
purposes
 
8.
 
Able to provide proof of identity to the 
satisfaction of the study clinician co
mpleting the 
enrollment process
 
 
9.
 
Physical examination and laboratory results without clinically significant findings and a 
Body Mass Index (BMI) ≤ 40 within the 
28 
days 
before
 
enrollment
 
Laboratory Criteria within 
28 
days 
before
 
enrollment
 
10.
 
White blood cells (WBC) and differential either within 
institutional normal
 
range or 
accompanied by the site Principal Investi
gator (PI) or designee approval
 
11.
 
Total lymphocyte count ≥ 800 cells/mm
3
 
12.
 
Platelets = 125,000 
–
 
5
00,000/mm
3
 
13.
 
He
moglobin within 
institutional normal
 
range
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
16
 
of 
54
 
14.
 
Serum iron 
either 
within 
institutional normal
 
ran
ge
 
or 
accompanied by the site PI or 
designee approval
 
15.
 
Serum ferritin within institutional normal range
 
or accompanied by the site PI or designee 
approval
 
16.
 
Alanine am
inotransferase (ALT) 
≤ 1.25 x institutional upper limit of normal 
(
ULN)
 
17.
 
Aspartate aminotransferase (AST) 
≤ 1.25 x institutional ULN
 
 
18.
 
Alkaline phosphatase (ALP) 
<
1.1 x institutional ULN
 
19.
 
Total bilirubin within institutional 
normal range
 
20.
 
Serum c
reatinine ≤ 1.1 x 
institutional ULN
 
21.
 
Negative for HIV infection by 
an
 
FDA
-
approved method of detection
 
Criteria applicable to women of childbearing potential
:
 
2
2
.
 
Negative beta
-
human chorionic gonadot
ropin (β
-
HCG) pregnancy test (urine or serum) 
on
 
the
 
day
 
of enrollment 
 
2
3
. 
Agrees to use an effective means of birth control from at least 21 days prior to enrollment 
through 
the 
end of the study
 
4.1.2
 
Exclusion Criteria
 
A 
s
u
bj
e
ct
 
will 
be excluded
 
if one or more of the following conditions apply
:
 
1.
 
B
reast
-
feeding or planning to become pregnant during the study. 
 
Subject has received any of the following substances
:
 
2.
 
More than 
10
 
days of systemic immunosuppressive medications or cytotoxic medications 
within the 
4
 
weeks 
prior to
 
enrollment or any within the 14 days 
prior to
 
enrollment 
 
3.
 
Blood products within 16 weeks 
prior to
 
enrollment
 
4.
 
Live attenuated vaccines within 
4
 
weeks 
prior to
 
enrollment
 
5.
 
Inactivated vaccines within 2 weeks prior to enrollment 
 
6.
 
Investigational research agen
ts within 
4
 
weeks 
prior to
 
enrollment or planning to receive 
investigational products while on the study
 
7.
 
Current a
llergy treatment with a
llergen immunotherapy
 
with antigen injections
, unless on 
maintenance
 
schedule
 
8.
 
Current anti
-
TB prophylaxis or 
therapy
 
9.
 
Pr
evious 
investigational 
H
1
 
influenza vaccine
 
10.
 
Previous investigational 
ferritin
-
based
 
vaccine
 
11.
 
Receipt of a
 
licensed 
influenza vaccine within 6 weeks before trial enrollment
 
 
Subject has a history of any of the following clinically significant 
conditions
:
 
12.
 
Serious reactions to vaccines that preclude receipt of study vaccinations as determined by 
the investigator 
 
13.
 
Hereditary 
angioedema,
 
acquired angioedema, or idiopathic forms of angioedema
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
17
 
of 
54
 
14.
 
Asthma that is 
not well controlled
 
 
15.
 
Diabetes mellitus (ty
pe I or II), 
with the exception of
 
gestational diabetes
 
16.
 
Thyroid disease that is not well controlled
 
17.
 
Idiopathic urticaria within the past year
 
18.
 
 
A
utoimmune disease or immunodeficiency
 
19.
 
Hypertension that is not well controlled
 
(
b
aseline systolic 
>
 
140 mmHg
 
or 
diastolic 
>
 
9
0
 
mmHg)
 
20.
 
Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet 
disorder requiring special precautions) or significant bruising or bleeding difficulties with 
IM injections or blood draws
 
21.
 
Malignancy that is ac
tive or 
history of 
malignancy that is likely to recur during the period 
of the study
.
 
22.
 
Seizure disorder other 
than
 
1) febrile seizures, 2) seizures secondary to alcohol 
withdrawal more than 
3
 
years ago, or 3) seizures that have not required treatment within
 
the last 
3
 
years
 
23.
 
Asplenia, functional asplenia or any condition resulting in the absence or removal of the 
spleen
 
24.
 
Guillain
-
Barré Syndrome
 
25.
 
Any medical, psychiatric, social condition, occupational reason or other responsibility 
that, in the judgment of the investigator, is a contraindication to protocol participation or 
impairs a 
subject’s 
ability to give informed consent.
 
 
C
LINICAL 
P
ROCEDURES
 
AND 
E
VALUATIONS
 
Evaluation 
of
 
this vaccine will include laboratory tests, medical history, physical assessment by 
clinicians, and subject self
-
assessment recorded on a diary card for 
7
 
days after each injection. 
Potential adverse reactions will 
be further evaluated
 
prior to
 
continuing the 
vaccination 
schedule. 
The schedule 
of 
study evaluations is described in this section and shown in table format in 
Appendix I
.
 
4.2.1
 
Screening
 
Screening for this study will 
be completed
 
through the 
VRC
’s screening protocol, VRC 500 
(NIH 11
-
I
-
0164
, 
[STUDY_ID_REMOVED]
). 
Subjects
 
will be recruited through Institutional Review Board 
(IRB)
-
approved advertising. The evaluations and sample collection
s
 
that will 
be included
 
in 
screening are a medical history, physical exam, laboratory tests needed to confirm e
ligibility, and 
pregnancy 
test 
for females of reproductive potential. 
 
If screening evaluations suggest a current concerning health condition or infection
,
 
such as 
hepatitis, 
then 
appropriate lab
oratory
 
tests may be conducted to evaluate these conditions. 
Additional assessments of 
health may 
be conducted
 
at screening based on clinical judgment. 
Screening evaluations for specific eligibility criteria (
Section
 
4.1
) must be completed within the
 
time interval specified 
prior to
 
enrollment for the given parameter and may be repeated, as 
needed, to confirm eligibility. Research blood samples will 
be collected
 
during screening; 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
18
 
of 
54
 
although 
generally
 
collected in 
the
 
28 
days 
prior to
 
enrollment
; 
a particular interval of time 
prior 
to
 
enrollment for 
collection
 
of these samples 
is not 
required
.
 
The informed consent 
form (ICF) 
will 
be reviewed
 
and counseling related to pregnancy 
prevention will 
be provided
.
 
Subjects
 
who are not up to dat
e on standard vaccinations may receive these, if available, during 
their participation in the screening protocol or at a later date during study participation. As part 
of the informed consent process, an Assessment of Understanding (AoU) 
is completed
 
on th
e 
day the subject is scheduled to enroll 
prior to
 
signing the 
VRC 321
 
protocol 
ICF
. Incorrect 
answers will 
be explained
 
to the 
subject
, who will sign the 
ICF
 
only after the study clinician is 
satisfied with the 
subject’s
 
understanding of the study.
 
4.2.2
 
Study S
chedule 
 
The Schedule of Evaluations in 
Appendix I
 
provides details on the study schedule
, 
the permitted 
windows
 
for completing the visits, and the evaluations to be performed at each visit
. 
The visit 
schedule is based on intervals of time af
ter each study injection (
Appendix I
).
 
The
 
clinician
s
 
will 
discuss the target dates and timing of the study 
vaccination
(s) and sample collections
 
with each 
subject
 
be
fore completing enrollment to help ensure that subject
s
 
can comply with the projected 
schedule.
 
After enrollment, deviations from the visit windows are discouraged and will be recorded as 
protocol 
deviations but
 
are permitted at the discretion of the PI (o
r designee) in the interest of 
completing the vaccination schedule and obtaining subject safety and immunogenicity 
evaluations.
 
4.2.3
 
Enrollment
 
The study has staged enrollment with required interim safety reviews, as described in Section 
4.3, for dose escalation, continuing enrollment, and second product administration. The first 
three subjects of Groups 1 and 2A will be enrolled with no more than
 
one subject per day. 
 
S
ubjects will be
 
stratified by age into Group 
2
A,
 
2
B, 
2
C, 
and 
2D
.  
 
The pharmacy database will be set up prior to opening the study to accrual. The group 
assignment 
is 
known to the staff and subject 
before
 
completing the electronic e
nrollment into the 
study on Day 0. 
Any subject who receives at least one study injection will be expected to 
continue with follow
-
up through the end of the study.
 
4.2.4
 
Acceptable 
and 
E
ffective 
Methods
 
of 
B
irth 
C
ontrol
 
Women of reproductive potential 
are
 
require
d to agree to use
 
an
 
acceptable and effective method 
of 
birth control beginning 21 days prior to enrollment and continuing through end of study.
 
Acceptable
 
and
 
effective 
methods
 
of birth control 
for women of reproductive potential in this 
study 
include
:
 
abstinence (no sex) with male partners, birth control pills or patch, condoms, 
Medroxyprogesterone acetate
 
(MPA) 
injection, diaphragm or cervical cap, 
intrauterine device 
(
IUD
)
, Implant (Nexplanon®
), NuvaRing®, partner
 
has vasectomy, or use of spermicides.
 
4.2.5
 
Vaccine 
Administration 
 
All study 
injections
 
will 
be completed
 
according to the assigned 
group
 
and 
will 
be administered
 
IM in the deltoid muscle.
  
Scheduled b
lood 
collection
 
must 
be 
completed
 
before vaccinations.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
19
 
of 
54
 
On the injection day (
prior to
 
injection
)
,
 
study subjects will be 
clinically 
evaluated
 
and samples 
will 
be collected
 
a
s per Schedule of Evaluations
 
(
Appendix I
)
. 
A subject who arrives at the clinic 
with fever or evidence of an
 
acute illness 
that
 
precludes 
administration of the vaccine may be 
rescheduled 
within the 
allowed study
 
visit window
.
 
Pregnancy test results for women of reproductive potential must be obtained on each injection 
day prior to the study injection and the results must be negative to proce
ed.
 
When choosing an arm for injection, clinicians should consider whether there is an arm injury, 
local skin problem or significant tattoo that precludes administering the injection or 
will
 
interfere 
with evaluating the arm after injection. 
 
Subjects enro
lled in
 
Group 1
will 
be observed
 
for a minimum of 1 hour
 
following the injection
. 
Vital signs (temperature, blood pressure, pulse and respiratory rate) will be collected at least 1 
hour after the injection, 
prior to
 
subject departure from the clinic. 
 
Subje
cts enrolled in 
Group 
2A, 
2B, 2C, and 2D 
will 
be observed
 
for a minimum of 30 minutes
 
following each injection
; vital signs will 
be collected
 
after at least 30 minutes. 
 
For all subjects
,
 
t
he injection site will 
be inspected
 
for evidence of local reaction
 
following the 
observation period
. 
 
In keeping with the NIH 
CC
 
policy and good medical practice, acute medical care will 
be 
provided
 
to subjects for any immediate allergic reactions or other injury resulting from 
participatio
n in this 
research 
study.
 
 
4.2.6
 
7
-
Day Solicited Reactogenicity and Follow
-
up
 
Subjects will be given a “Diary Card” to use as a memory aid, on which 
they can 
record 
temperature and symptoms daily for 
7
 
days after each injection. Subjects will be trained and 
enco
uraged to use the secure electronic 
database but
 
will have the option to complete a paper 
diary card. When the diary card parameters are recorded directly by the subject 
in the 
electronic 
database, the subject’s electronic record will be the source for the
se data. When 
collected
 
on 
paper
, the paper diary card will be 
the 
source document
. 
When neither
 
paper
 
nor electronic diary 
is available from the subject, the study clinician will document the source of reactogenicity 
information recorded in the study data
base.
 
The solicited signs and symptoms on the diary card will include the following parameters: 
unusually tired/feeling unwell, muscles aches (other than at injection site), headache, chills, 
nausea, joint pain, and pain/tenderness
, redness, swelling, 
skin
 
lesions
 
at injection site. Subjects 
will also record the day’s highest measured temperature and measurement of largest diameter for 
redness and swelling at injection site. 
 
Follow
-
up on subject well
-
being will be performed by telephone
 
on 
the 
first
 
day following all
 
injections
 
and by clinic visits as shown in the Schedule of Evaluations (
Appendix I
)
.
 
Events following any study injection that may require clinica
l evaluation include rash, urticaria, 
fever of 38.5˚C (Grade 2) or higher lasting greater than 24 hours, or significant impairment in the 
activities of daily living. Additionally, other clinical concerns may prompt a study visit based on 
the judgment of a 
study 
clinician.
 
4.2.7
 
Follow
-
Up through End of Study
 
Group 1
: 
S
tudy 
follow
-
up will continue via clinical visits through 
52
 
weeks after the study 
injection
 
and through 
an
 
influenza season
.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
20
 
of 
54
 
Group
s
 
2
A, 2B, 2C,
 
and
 
2D
: 
S
tudy 
follow
-
up will continue via clinical visits through 
52
 
weeks 
after the 
last
 
study injection
 
and through
 
an
 
influenza season
.
 
4.2.8
 
Mucosal Sample Collection
 
Throughout the study, nasopharyngeal swabs for diagnostic purposes will be requested from 
subjects who me
et criteria for influenza
-
like illness (ILI) as defined in Section 
5.1
.
 
4.2.9
 
Blood Sample Collection
 
At intervals throughout the study, blood will 
be drawn
 
for safety and immunologic assays. Blood 
will 
be drawn
 
from the arm veins of subjects by standard phlebotomy pr
ocedures. Total blood 
volume drawn from each subject will not exceed the NIH CC 
g
uidelines
.
 
4.2.10
 
A
pheresis
 
Group 2 subjects 
will 
be offered
 
apheresis 
as an optional procedure at 
Visit 0
9
 
in order to collect 
blood cells of special interest
 
for research
. 
The
 
aphe
resis
 
procedure will be carried out by trained 
Department of Transfusion Medicine (DTM) medical staff using automated cell separator 
devices. 
 
A
pheresis performed 
for
 
this protocol will be performed solely for research purposes. 
All study 
subjects will be treated according to standard 
DTM 
whole blood and apheresis donation policies 
and procedures.
 
Prior to the schedul
ing apheresis
, the subject must have a venous assessm
ent 
performed by the DTM staff
. 
 
In order to undergo apheresis procedures, a subject must 
meet the apheresis eligibility criteria
 
as 
described in Section 
4.2.11
 
and 
have no medical contraindications
, as determine
d
 
by the DTM 
staff
.  A 
VRC 
study clinician will complete
 
a checklist for apheresis 
eligibility before referring a 
subject
 
for the procedure
.  
 
 
Prior to beginning the apheresis procedure, a study clinician may request in advance that other 
laboratory 
samples
 
be collected as needed to monitor the well
-
being of the subject or 
if
 
needed 
by a research laboratory. 
 
In addition, for 
women of reproductive potential, a 
p
regnancy test
 
by 
blood or urine
 
will be performed
 
by a VRC study clinician within 72 hours prior to the apheresis 
procedure. Results must be negative to proceed with apheresis
.  
 
The Dowling Apheresis Clinic staff at the
 
NIH 
CC
 
routinely performs a hemoglobin test prior to 
initiating apheresis, per DTM Apheresis Clinic standard policies. If a subject is found to have a 
hemoglobin value less than permitted by the Apheresis Clinic, then the apheresis will not be 
initiated,
 
and the ordering provider will be notified. 
 
In this study, the procedure will require two antecubital venous access sites and will involve 
processing 1 to 4 liters of whole blood. The expected mononuclear cell yield is approximately 
0.5 to 1.0 x 10
9
 
cells
 
per liter processed, and the apheresis device can process about 2
 
to 
3 liters 
per hour. Thus, 1 to 2 hours are required to process 1 to 4 liters of blood and obtain about 1
 
to 
4 
x 10
9
 
leukocytes. The packed red cell loss during the procedure is the equiva
lent of a 
6
 
mL blood 
draw; this is the volume that will 
be used
 
for the purposes of calculating cumulative blood draw 
when apheresis is performed.
 
During or following an apheresis visit, if there is any concern about the well
-
being of the subject, 
the DTM 
clinic may conduct appropriate medical evaluations by history
-
taking, physical 
examination, laboratory tests, and/or other testing.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
21
 
of 
54
 
Research blood samples will be processed and stored at 
VIP
 
or
 
a collaborating research 
laboratory. 
Stored samples may be use
d later 
to further evaluate immune responses
 
and to 
elucidate genetic factors associated with immune response.
 
4.2.11
 
Apheresis Eligibility Criteria
 
Subject
 
must meet all of the following criteria: 
 
1.
 
Afebrile (temperature 
<
 
37.5
0
C)
 
2.
 
Weight ≥110 pounds
 
3.
 
Adequate bilateral antecubital venous access
 
4.
 
Hemoglobin 
>
 
12.5 g/dL for females; 
>
 
13.0 g/dL for men
 
5.
 
Platelets > 150,000 K/uL
 
6.
 
No c
ardiovascular instability as indicated by a) history of medically significant cardiac 
arrhythmia within the last 12 months, or
 
b) ischemic cardiovascular disease within the last 12 
months, or c) heart rate outside of the 50 
-
 
100 beats/minute interval (on 3 successive 
readings), or d) blood pressure greater than 180 mmHg (systolic) or 100 mmHg (diastolic) on 
3 successive readings
 
7.
 
No current lung or kidney disease 
 
8.
 
No known coagulation disorder
 
9.
 
No sickle cell disease 
 
10.
 
No active or chronic hepatitis 
 
11.
 
No intravenous injection drug use in the past 5 years 
 
12.
 
Not breast feeding
 
13.
 
Negative beta
-
human chorionic gonadotropin (β
-
HCG) pregnancy
 
test (urine or serum) 
performed by a VRC study clinician within 72 hours prior to the apheresis procedure
 
 
4.2.12
 
Concomitant Medications
 
Only routine prescription medications will 
be
 
entered
 
in the database at the time of enrollment.  
Subsequently, 
the only 
con
comitant medications
 
that will be recorded or updated in the database 
are those
 
associated with an AE requir
ing
 
expedited reporting or the development of a new 
chronic condition requiring ongoing medical management. 
Anti
-
viral medications taken during 
in
fl
u
enza
 
or 
in
flu
enza
-
like illnesses will be recorded in the database.
 
Receipt of 
a FDA
-
approved
 
vaccine at any time during the study will 
be recorded
 
in the database (clinicians should work 
with subjects regarding the timing of licensed vaccines 
relative to
 
study injection). 
Otherwise, 
concomitant medications taken throughout the study will be recorded in the subject’s 
study 
chart
 
and general medical r
ecord
 
for general medical documentation but will not 
be recorded
 
in the 
database.  
 
 
C
RITERIA FOR 
D
OSE 
E
SCALATION
 
AND 
D
OSE 
C
ONTINUATION
 
 
There 
will be
 
one
 
dose esc
alation
 
review and 
two
 
dose continuation review
s
 
in this study. 
The 
Protocol Safety Review Team (PSRT, Section 
8.8
) will conduct an interim safety data review 
before dose escalatio
n 
or
 
repeat dosing 
may occur. 
The PSRT must assess the data as showing no 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
22
 
of 
54
 
significant safety concerns before enrollment of the
 
next dose level and repeat dosing at the same 
level
 
may proceed
.
 
Enrollment will begin in 
Group
 
1
 
(
20 mcg of 
VRC
-
FLUNPF099
-
00
-
VP
) 
with no more 
than one 
subject enrolled per day.
 
Two weeks after vaccination of 
the 
third
 
subject
, there will be an 
interim
 
safety review 
of 
available
 
data for
 
three
 
subjects to determine whether to 
continue 
enrollment in Group 1 and 
to 
proceed 
to 
the next dose level. If the 20 mcg dose of 
VRC
-
FLUNPF099
-
00
-
VP
 
is assessed
 
as safe, enrollment 
can 
contin
ue for Group 1 and 
begin for 
Group 2A.
 
In Group 2
A
 
(60 mcg of 
VRC
-
FLUNPF099
-
00
-
VP
)
,
 
enrollment 
will 
continue
 
with no more than 
one subject enrolled per day.
 
Two weeks after vaccination of the 
third
 
subject
, there will be an 
interim
 
safety review 
of the 
available 
data for 
three
 
subjects to determine whether to proceed to 
Groups 2B, 2C, and 2D
. If the 60 mcg dose of 
VRC
-
FLUNPF099
-
00
-
VP
 
is assessed
 
as safe, 
enrollment can continue for Group 2A and begin for Groups 2B, 2C, and 2D. Additi
onally, if the 
60 mcg dose is assessed as safe, all Group 2 subjects may receive the second vaccination at week 
16
.
 
Additional 
subjects may be enrolled into 
a 
group 
in order to
 
have the requisit
e 
data 
for
 
at least 
3
 
subjects
, i
f first 
vaccination
s
 
are 
not completed
 
or there are discontinuations from the study 
before there are sufficient data to conduct the dose escalation 
and continuation 
review for 
that
 
group
.
 
The IRB will 
be provided
 
with documentation of the safety review process and
 
notification of 
the dose escalation.
 
Consultation with the IRB and FDA, if needed, as per study pause criteria 
(Section 
4.5
) will occur if indicated by the 
review. One outcome of a dose escalation review may 
be to recommend evaluation of additional subjects at the current dose level and reassess for 
safety before proceeding to a higher dose level
 
and repeat dosing at the same dose level
. 
 
 
C
RITERIA FOR 
D
ISCONT
INUING 
S
TUDY 
I
NJECTIONS 
OR 
P
ROTOCOL 
P
ARTICIPATION
 
Decisions 
by the PI or designee
 
to discontinue 
study injections or protocol participation for a 
subject will 
be made
 
with these criteria
.
 
4.4.1
 
Discontinuation
 
of 
Study 
Injections
 
A subject 
will
 
be 
discontinu
ed
 
f
rom 
receiving study product
 
for the following reasons
:
 
1.
 
Subject voluntar
il
y withdraws
 
2.
 
Pregnancy
 
3.
 
Grade 3 
unsolicited 
AE assessed as 
possibly, probably or definitely related to study 
product 
 
4.
 
Grade 4 AE assessed as related to study 
product
 
5.
 
Immediate hypersensitivity reaction associated with study product
 
6.
 
Intercurrent
 
illness that is not expected to resolve 
prior to
 
the next scheduled study 
injection
 
7.
 
Treatment with systemic glucocorticoids (e.g.
, prednisone or 
other glucocorticoid
) or 
other immunomodulators (other than nonsteroidal anti
-
inflammatory drugs [NSAIDs]), 
with the exception that study 
injections 
may continue per investigator discretion if the 
next 
dose 
occurs at least 
2
 
weeks following
 
complet
ion of glucocorticoid treatment
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
23
 
of 
54
 
8.
 
The study PI assess
es
 
that it is not in the best interest of the subject to continue the 
vaccination schedule
 
Group 2 s
ubjects who
 
do not 
receive
 
the second injection as scheduled 
are expected to continue 
follow
-
up according to the Schedule of Evaluations
 
for Group 1 subjects, 
except that research 
sample collections will be discontinued for pregnant women or others in which it is 
contraindicated
.
 
 
4.4.2
 
Discontinuation 
from
 
Protocol Participation
 
A subject
 
will
 
b
e discontinued
 
from protocol participation for the following reasons:
 
1.
 
Subject 
voluntar
il
y withdraws
 
2.
 
Subject develops a medical condition that is a contraindication to continuing study 
participation
 
3.
 
The IND 
S
ponsor or regulatory authority stops the 
protocol
 
4.
 
The 
IND 
S
ponsor or 
PI assesses that is it not in the best interest of the subject to continue 
participation in the study or that the subject’s compliance with the study is not sufficient
 
 
C
RITERIA FOR 
P
AUSING 
AND 
R
ESUMING 
THE 
S
TUDY
 
4.5.1
 
Plan for Pausing
 
the Study
 
The PI 
and Protocol Safety Review Team (PSRT) 
will closely monitor and analyze study data as 
they become available and will make determinations regarding the presence and severity of AEs. 
The administration of study injections and new enrollments will 
be paused
 
and the IND Sponsor 
will 
be promptly not
ified
 
according to the following criteria:
 
•
 
One
 
(or more) subject experiences a 
SAE
 
or 
Grade 4
 
AE 
assessed as related to study 
product.
 
•
 
Two
 
(or more) subjects experience the same 
Grade 
3
 
unsolicited AE
 
assessed as 
possibly, probably or 
definit
e
ly 
related to
 
study product.
 
•
 
T
hree
 
(or more) subjects experience the same 
Grade 2
 
or higher laboratory 
abnormality 
assessed as 
possibly, probably or 
definit
e
ly 
related to study product.
 
•
 
One 
(or more) subject experiences ulceration, abscess, or necrosis at the injection
 
site.
 
S
elf
-
limited solicited reactogenicity 
that is not an SAE 
will not be counted towards pause 
criteria
.
 
4.5.2
 
Plan for Review of Pauses and Resuming 
the Study
 
The IND Sponsor, with participation by the
 
PI and
 
PSRT
, 
will conduct the review and make the 
decision to resume
, amend
 
or close the study
 
and notify the IRB accordingly
.  
As 
part of the 
pause review, the reviewers will also advise on whether the study needs to be paused 
again for 
any subsequent
 
AEs 
of the same type. 
 
The pause criterion for the SA
E will continue to apply
.
 
The administration of study injections and new enrollments would resume only if review of the 
events
 
that caused the pause resulted in a recommendation to permit further study injections and 
enrollments. Safety data reports and ch
anges in study status will be submitted to relevant 
regulatory authorities 
in accordance with
 
Section 
5
 
and institutional policy.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
24
 
of 
54
 
 
SAFETY AND ADVERSE E
VENT 
REPORTING
 
 
A
DVERSE 
E
VENTS
 
Adverse Event (AE) 
-
 
Any untoward medical occurrence in a human subject, including any 
abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or 
disease, temporally associated with the subject’s partici
pation in research, whether or not 
considered related to the subject’s participation in the research. In the context of FDA
-
required 
reporting, an AE means any untoward medical occurrence associated with the use of a drug in 
humans, whether or not consider
ed drug related.
 
Each AE will be graded according to the Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, Food and Drug 
Administration Guidance 
–
 
September 2007 (
Appendix II
). The following guidelines will be used 
to determine whether or not an AE is recorded in the study database:
 
•
 
Solicited 
AEs
 
(
i.e.
,
 
reactogenicity parameters
 
as defined in 
S
ection 
4.2.6
) will be 
recorded 
without attribution assessments 
by the subject 
on
 
paper or 
an 
electronic diary 
card for 
7
 
days after 
each injection. If 
the 
paper diary card is completed by subject, data 
will be transcribed by
 
a
 
clinician in
to
 
the study database. 
Clinicians will follow and 
collect resolution information for any reactogenicity symptoms that are not resolved 
within 7 days.
 
•
 
All unsolicited AEs will 
be recorded
 
with attribution assessments
 
in the study database 
from receipt of 
the 
first study injection
 
through 
completion of 
the
 
4
 
w
eek 
visit
 
that 
follows
 
each study injection
.
 
At other periods between injections and 
following
 
the 
4
 
week
 
post
-
injection visit
 
after the 
second
 
vaccination 
through the last study visit
, only 
SAEs (Section 
5.2
), new chronic medical conditions, and influenza or 
ILI
 
will 
be 
recorded
. 
 
•
 
Cases of influenza or influenza
-
like illness 
(ILI) 
will be evaluated 
as follows:
 
I
LI
 
is defined as fever (temperature of 100
0
F [37.8
0
C
] or greater) and a cough and/or sore 
throat in the absence of a known cause other than influenza.
 
Collection of
 
nasopharyngeal 
swab
s
 
will be used 
for laboratory confirmation
 
of influenza 
by 
polymerase chain reaction 
(
PCR
)
 
in s
ubjects who meet criteria for ILI
. 
 
The severity of illness in subj
ects with 
laboratory confirmed influenza illness will be 
recorded on a
 
case report
 
form rather than 
on an 
AE
 
form. 
 
 
S
ERIOUS 
A
DVERSE 
E
VENTS
 
The term “Serious Adverse 
Event
”
 
(SAE)
 
is define
d in 21 CFR 312.32 as follows: 
“
An adverse 
event or 
suspected adverse reaction is considered serious if, in the view of either the investigator 
or the sponsor, it
 
results in any of the following outcom
es:
 
Death, a life
-
threatening adverse 
event
, inpatient hospitalization or prolongation of existing hospital
ization, a persistent or 
significant incapacity
 
or substantial disruption of the ability to conduct normal life functions
, or a 
congenital anomaly/b
irth defect.
 
Important medical events that may not result in death, be life
-
threatening, or require hospital
ization may 
be considered
 
serious 
when,
 
based upon appropriate 
medical judgment, they may jeopardize the 
patient or 
subject
 
and may
 
require medical or 
surgical intervention to prevent one of the outco
mes listed in this definition. 
Examples of such 
medical 
events include allergic bronchospasm requiring intensive treatment
 
in an emergency 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
25
 
of 
54
 
room or at home
, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization,
 
or the development of drug dependency or drug abuse.”
 
“Life
-
threatening” re
fers to an 
AE
 
that at occurrence represents an immediate risk of death to the 
subject. 
It does not include an AE or suspected adverse reaction that, had it occurred in a more 
severe form, might have caused death.
 
Similarly, a hospital admission for an elec
tive proce
dure 
is not considered 
a SAE
.
 
 
A
DVERSE 
E
VENT 
R
EPORTING TO THE 
IND
 
S
PONSOR
 
AEs that meet SAE criteria must be reported and submitted by the clinical site on an expedited 
basis to the IND Sponsor, VRC/NIAID/NIH, according to sponsor 
guidelines as follows:
 
 
•
 
R
esults
 
in death
;
 
•
 
I
s life threatening
 
(places the subject at immediate risk of death from the event as it 
occurred);
 
•
 
Results in inpatient hospitalization or prolongation of existing hospitalization;
 
•
 
R
esults in persistent or signific
ant disability/incapacity
;
 
•
 
Results in 
a congenital anomaly/birth defect in the offspring of a study subject
; OR
 
•
 
Based upon appropriate medical judgment, may jeopardize the subject’s health and may 
require medical or surgical intervention to prevent one of 
the other outcomes listed in this 
definition (examples of such events include allergic bronchospasm requiring intensive 
treatment in the emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the deve
lopment of drug dependency or drug abuse).
 
In addition
, any event, regardless of severity, which in the judgment of 
an investigator 
 
represents a 
SAE
, may be reported on an expedited basis.
 
An investigator 
must 
communicate an initial SAE report within 24 hours of site awareness of 
occurrence to the IND 
S
ponsor 
data entry into the database, which triggers an alert to the IND 
Sponsor MO. Within 3 working days, a written summary by the investigator should be submitt
ed 
to the IND Sponsor.
 
In order for
 
the IND Sponsor to comply with regulations mandating sponsor notification of 
specified SAEs to the FDA within 7 or 15 calendar days, the investigator must submit additional 
information as soon as it is available.  
 
5.3.1
 
IND S
ponsor Reporting to the FDA
 
The 
IND Sponsor
 
is responsible for
 
mak
ing
 
the determination of which SAEs are “serious and 
unexpected suspected adverse reactions” (SUSARs) as defined in 21 CFR 312.32.
 
The following 
definitions apply:
 
•
 
Suspected adverse reaction
 
means any AE for which there is a reasonable possibility that 
the 
st
ud
y
 
product
 
caused the AE.
 
•
 
Unexpected Adverse Event
 
means an AE that is not listed in the 
IB
 
or 
is not listed
 
at the 
specificity or severity that has 
been observed
.  
 
All SUSARs 
(
as determined by the IND Sponsor
)
 
will be reported to the FDA as IND Safety 
Reports
 
per 21 CFR 312.32 as soon as possible but not exceeding 7 calendar days for unexpected 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
26
 
of 
54
 
fatal or life
-
threatening events, and not exceeding 15 calendar days for other qualifying events. 
IND Safety Reports w
ill 
also 
be provided to the IRB.
 
The IND Sponsor will also submit an IND Annual Report of the progress of the investigation to 
the FDA as defined in 21 CFR 312.33.
 
 
R
EPORTING TO THE 
I
NSTITUTIONAL 
R
EVIEW 
B
OARD
 
The following information is consistent with NIH
 
IRB Policy 801: Reporting Research Events, Version 1, 
effective July 1, 2019. 
 
Reportable Event 
-
 
An event that occurs during the course of human subject research that requires 
notification to the IRB.
 
For the purposes of this policy, reportable events in
clude the following:
 
•
 
Unanticipated Problems (UPs) involving risks to subjects or others
 
•
 
Non
-
compliance (including major protocol deviations and noncompliance that is not related to a 
protocol deviation)
 
•
 
Deaths related or possibly related to research activi
ties
 
•
 
New information that might affect the willingness of subjects to enroll or continue participation in 
the study
 
5.4.1
 
Unanticipated Problem
 
A
n
 
u
nanticipated 
p
roblem (UP) 
is 
defined as any incident, experience, or outcome that meets all 
three of the following
 
criteria:
 
•
 
U
nexpected 
(
in
 
terms of
 
nature, severity, or frequency
)
 
given (a) the research procedures 
that are described in the protocol
-
related documents, such as the IRB approved research 
protocol and informed consent document; and (b) the characteristics
 
of the subject 
population being studied; and
 
•
 
R
elated 
or possibly related 
to participation in the research
 
(possibly related means there is 
a reasonable possibility that the incident, experience, or outcome may have been caused 
by the procedures involved i
n the research); and
 
•
 
S
uggests that the research 
places subjects or others 
(which may include research staff, 
family members or other individuals not directly participating in the research) at a greater 
risk of harm (including physical, 
psychological, economic, or social harm) related to the 
research than was previously known or expected.
 
A UP must be reported within 7 calendar days of an investigator becoming aware of the actual or 
suspected UP.
 
5.4.2
 
Protocol 
Deviation 
 
A 
protocol 
deviation
 
(PD)
 
is defined
 
as any change, divergence, or departure from 
the IRB
-
approved study procedures in a research protocol
 
and are further characterized as major and 
minor as follows:
 
•
 
Major Deviations
 
–
 
Deviations from the IRB approved protocol that h
ave, or may have 
the potential to, negatively impact, the rights, welfare or safety of the subject, or to 
substantially negatively impact the scientific integrity or validity of the study. 
 
•
 
Minor Deviations
 
–
 
Deviations that do not have the potential to ne
gatively impact the 
rights, safety, or welfare of subjects or others, or the scientific integrity or validity of the 
study.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
27
 
of 
54
 
For the reporting purposes, failure of subjects to comply with the research protocol does not 
represent non
-
compliance unless that f
ailure is due to an action or omission of a member of the 
research team, for example, the failure to give adequate instruction to the subject.
 
A major deviation must be reported within 7 calendar days of an investigator becoming aware of 
an actual or suspe
cted deviation. Although PDs are also non
-
compliance, these should only be 
reported once as deviations. Major deviations resulting in death must be reported within 24 hours 
of the occurrence of the event or of any member of the study team becoming aware of
 
the death.
 
Researchers are responsible for monitoring their studies throughout the year for adherence to the 
IRB approved protocol. The purpose of this monitoring is to identify major deviations and to 
look for trends in minor deviations that may indicate
 
a systemic issue in how the study is being 
conducted that could potentially negatively impact the rights, safety, or welfare of participants or 
the study’s ability to produce scientifically valid results. A series of minor deviations pointing 
toward a mor
e global issue that could affect the rights, safety or welfare of the participant or 
affect the validity of the study should be reported as a major deviation. In all other instances, a 
summary of minor deviations should be provided to the IRB at the time o
f continuing review.
 
5.4.3
 
Non
-
Compliance 
 
Non
-
compliance is the failure of investigator(s) to follow the applicable laws, regulations, or 
institutional policies governing the protection of human subjects in research, or the requirements 
or determinations of the
 
IRB, whether intentional or not.
 
Non
-
compliance may be unintentional (e.g. due to lack of understanding, knowledge, or 
commitment), or intentional (e.g. due to deliberate choice to ignore or compromise the 
requirements of any applicable regulation, organi
zational policy, or determination of the IRB).
 
Non
-
compliance is further characterized as serious or continuing as follows:
 
•
 
Serious non
-
compliance
 
–
 
Non
-
compliance, whether intentional or not, that results in 
harm or otherwise materially compromises the ri
ghts, welfare and/or safety of the subject. 
Non
-
compliance that materially effects the scientific integrity or validity of the research 
may be considered serious non
-
compliance, even if it does not result in direct harm to 
research subjects.
 
•
 
Continuing non
-
compliance
 
–
 
A pattern of recurring non
-
compliance that either has 
resulted, or, if continued, may result in harm to subjects or otherwise materially 
compromise the rights, welfare and/or safety of subjects, affect the scientific integrity of 
the study or
 
validity of the results. The pattern may comprise repetition of the same non
-
compliant action(s), or different noncompliant events.
 
Any actual or suspected non
-
compliance by any investigator or entity associated with the 
protocol must be reported to the I
RB by the PI/designee within 7 calendar days of any 
investigator or individual associated with the protocol first becoming aware.
 
5.4.4
 
Death
 
Any death of a research subject that is possibly, probably or definitely related to the research must be 
reported within
 
24 hours of an investigator becoming aware of the death.
 
5.4.5
 
New Information
 
New information that might affect the willingness of a subject to enroll or remain in the study should be 
reported within 7 calendar days of an investigator first becoming aware.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
28
 
of 
54
 
5.4.6
 
Sus
pension or Termination of Research Activities
 
Any suspension or termination of research activities, including holds on new enrollment, placed upon the 
research by the study sponsor, NIH or IC leadership, or any regulatory agency must be reported within 7 
c
alendar days of an investigator becoming aware.
 
5.4.7
 
Expedited Reporting to the IRB
 
Death related to research must be reported within 24 hours.
 
The following will be reported within 7 calendar days of investigator awareness: 
 
•
 
Actual or suspected UPs;
 
•
 
Actual or 
suspected non
-
compliance;
 
•
 
Actual or suspected Major PDs;
 
•
 
SAEs that are actual or suspected UPs;
 
•
 
New information that might affect the willingness of a subject to enroll or remain in the 
study;
 
•
 
Suspension or termination of research activities, 
including holds on new enrollment, 
placed upon the research by the study sponsor, NIH or IC leadership, or any regulatory 
agency.
 
5.4.8
 
Annual Reporting to the IR
B
 
The following will be reported to the NIAID IRB in summary at the time of Continuing 
Review:
 
•
 
Summary of UPs and non
-
compliance;
 
•
 
AEs, including SAEs, that are not UPs, as a narrative summary statement indicating 
whether these events were within the expected range;
 
•
 
Minor PDs (aggregate summary);
 
•
 
Any trends or events which in the opinion of t
he investigator should be reported.
 
 
STATISTICAL CONSIDER
ATIONS
 
 
O
VERVIEW
 
This is
 
a 
P
hase 
I, open
-
label, dose escalation study to evaluate the dose, safety, tolerability, and 
immunogenicity of 
VRC
-
FLUNPF099
-
00
-
VP
 
in
 
two dose
 
regimens
.
  
Study objectives can b
e 
found in Section 
3
.
 
 
E
NDPOINTS
 
6.2.1
 
Primary Endpoints: Safety
 
Assessment of product safety will include clinical observation and monitoring of hematological 
and chemical parameters. Reactogenicity will be closely mon
itored for 7 days after each 
injection and safety evaluated by clinical visits
 
for 52 weeks following the last vaccine 
administration and through 
an
 
influenza season
. See
 
Section
 
4.2
 
and 
Appendix I
 
for details and 
specified time points. The following parameters will be assessed for all study groups:
 
•
 
Occurrence of solicited local reactogenicity symptoms for 7 days 
after
 
each injection
 
•
 
Oc
currence of solicited systemic reactogenicity symptoms for 
7
 
days 
after
 
each injection
 
•
 
Change from baseline 
in 
safety laboratory measures
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
29
 
of 
54
 
•
 
Occurrence of AEs of all severities through 
the 
4 w
eek 
post
-
injection
 
visit
 
•
 
Occurrence 
at any time throughout the stud
y 
of SAEs or new chronic medical conditions 
that require ongoing medical management
.
 
6.2.2
 
Secondary Endpoints: Immunogenicity
 
The 
principal 
immunogenicity endpoint
s will be assessed by measuring HA
-
stem specific 
antibody 
by 
pseudo
-
neutralization assay at
:
 
 
•
 
Group 1: 
Baseline
 
(
Week 0/
Visit 02)
 
and
 
Week 2
 
(Visit 04)
 
after
 
vaccination
, and
 
•
 
Groups 2A
-
2D: 
Baseline
 
(
Week 0/
Visit 02) 
and Week 2 
(Visit 0
4
) 
after the first 
va
ccination, and at Week 16
 
(Visit 07)
 
and W
eek 
18 
(Visit 09) 
after the second 
vaccination
 
6.2.3
 
Exploratory Endpoints
: Immunogenicity
 
 
Exploratory immunogenicity evaluations may include t
he detection of antibody by MSD or 
micro
neutralization assay
,
 
and e
xploratory 
B and 
T cell assays
.
 
 
S
AMPLE 
S
IZE 
AND 
A
CCRUAL
 
Recruitment will target 
53
 
healthy adult participants 18 to 
7
0 years of age
, though up to 
70
 
participants may be enrolled if deemed necessary for safety or immunogenicity evaluations. 
 
Enrollment will
 
be spread over multiple groups. Group 1 will target 5 healthy adults 18 to 40 
years of age. Groups 2A, 2B, 2C, and 2D will target 1
2
 
healthy adult participants each, with each 
study 
group corresponding to a different age range.
 
6.3.1
 
Power Calculations for Safe
ty
 
The goal of the safety evaluation 
for
 
this study is to identify safety concerns associated with 
injections of the investigational vaccine. Primary sample size calculations for safety 
are 
expressed
 
in terms of
 
the ability to detect serious adverse experi
ences. Other sample size 
calculations for comparing the two vaccination groups on adverse experiences are similar to the 
calculations for immunogenicity (Section 
6.4.3
).
 
The ability of the study to identify SAEs will 
be expressed
 
in terms of
 
the probability of 
observing a certain number of 
SAEs
. Useful values are the 
minimum true
 
rate such that the 
probabil
ity of observing at least one event is at least 
90%,
 
and the maximum true rate such that 
the probability of not observing any event is at least 90%. 
 
For 
Group 1
 
(
dose
-
escalation
) within each group (n=5), there is 
a 
90
%
 
chance to observe at least 
1 SAE if 
the true rate is at least 
0.369
 
and over 
90
% chance to observe no SAE if the true rate is 
less than 
0.021
.
 
For 
Group
s
 
2A, 2B, 2C, 2D
 
within each group (n=1
2
), there is 
greater than
 
a 
90% chance to 
observe at least 1 SAE if the true rate is at least 
0.1
75
 
and over 
a
 
90% chance to observe no SAE 
if the true rate is no more than 
0.00
9
.
 
If Groups 2A, 2B, 2C, 2D are combined (N=
48
), there is 
greater than
 
a 90% chance to observe at 
least 1 S
AE if the true rate is at least 0.0
47
 
and 
greater than
 
a 90% chance to observe no SAE if 
the true rate is no more than 0.002
 
Probabilities of observing 0 or more than 1 
SAE 
within each group 
are presented
 
in 
Table 6
-
1
 
for a range of possible true event rat
es
 
and different sample sizes
. These calculations provide 
a 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
30
 
of 
54
 
complete
 
picture of the sensitivity of this study design to identify potential safety problems with 
the vaccine.
 
Table 6
-
2
 
gives the upper and lower bounds for 95% exact binomial confidence intervals of the 
true SAE rate at all possible numbers of events within ea
ch group (n=5 and n=1
2
). 
 
For 
Group 1
 
(n=5): If none of the 5 participant
s
 
receiving the vaccines 
experience
 
SAEs
, the 
95% exact 2
-
sided upper confidence bound for the SAE 
rate is 
0.52
.
 
For 
Group
s
 
2A, 2B, 2C, 2D
 
(n=1
2
): If none of the
 
1
2
 
participant
s
 
recei
ving the vaccines 
experience
 
SAEs
, the 95% exact 2
-
sided upper confidence bound for the SAE rate is 
0.2
65
.
 
 
Table 6
-
1: Probability of Events for Different Safety and Immunogenicity Scenarios
 
 
Group 1
 
(
dose
-
escalation
): 
N=5
 
Group
s
 
2A, 2B, 2C, 2D
: 
N=1
2
 
Group
s
 
2A, 2B, 2C, 2D 
combined
: N=
48
 
True 
Event 
Rate
 
Pr 
 
(observing 
0 event)
 
Pr 
 
(observing 
more than 1 
event)
 
Pr 
 
(observing 
0 event)
 
Pr 
 
(observing 
more than 1 
event)
 
Pr 
 
(observing 0 
event)
 
Pr 
 
(observing 
more than 1 
event)
 
0.01
 
0.951
 
0.001
 
0.8
86
 
0.0
06
 
0.
617
 
0.
083
 
0.02
 
0.904
 
0.004
 
0.7
85
 
0.0
23
 
0.
379
 
0.
249
 
0.05
 
0.774
 
0.023
 
0.
540
 
0.
1
1
8
 
0.0
85
 
0.
699
 
0.1
 
0.590
 
0.081
 
0.2
82
 
0.
341
 
0.
006
 
0.9
60
 
0.15
 
0.444
 
0.165
 
0.
142
 
0.
557
 
<0.001
 
0.99
6
 
0.2
 
0.328
 
0.263
 
0.0
69
 
0.
725
 
<0.001
 
>0.999
 
0.3
 
0.168
 
0.472
 
0.
014
 
0.9
15
 
<0.001
 
>0.999
 
0.4
 
0.078
 
0.663
 
0.002
 
0.9
80
 
<0.001
 
>0.999
 
0.5
 
0.031
 
0.812
 
<0.001
 
0.997
 
<0.001
 
>0.999
 
Table 6
-
2: 95% Confiden
ce Intervals for the True Rate a
t All Possible Observed Rates 
within a Group (n=
5 and n=
1
2
)
 
 
Group 1:
 
N=5
 
95% Confidence Interval
 
 
 
Group 2A, 2B, 2C, 2D
: N=1
2
 
95% Confidence Interval
 
Observed 
Rate
 
Lower Bound
 
Upper Bound
 
 
Observed 
Rate
 
Lower Bound
 
Upper Bound
 
0/5
 
0
 
0.522
 
 
0/1
2
 
0
 
0.2
65
 
1/5
 
0.005
 
0.716
 
 
1/
12
 
0.002
 
0.3
85
 
2/5
 
0.053
 
0.853
 
 
2/
12
 
0.0
21
 
0.4
84
 
3/5
 
0.147
 
0.947
 
 
3/
12
 
0.0
55
 
0.
572
 
4/5
 
0.284
 
0.995
 
 
4/
12
 
0.0
99
 
0.
6
51
 
5/5
 
0.478
 
1
 
 
5/
12
 
0.
152
 
0.
723
 
 
 
 
 
6/
12
 
0.
211
 
0.
789
 
 
 
 
 
7/
12
 
0.2
77
 
0.
848
 
 
 
 
 
8/
12
 
0.
349
 
0.
901
 
 
 
 
 
9/
12
 
0.
428
 
0.
945
 
 
 
 
 
10/
12
 
0.
516
 
0.
979
 
 
 
 
 
11/
12
 
0.
615
 
0.9
98
 
 
 
 
 
12/
12
 
0.
735
 
1
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
31
 
of 
54
 
6.3.2
 
Power Calculations 
for Immunogenicity
 
Table 6
-
1
 
gives the probabilities of observing 0 or more than 1 response over a range of 
underlying response rates
 
and different sample sizes
. 
 
Table 6
-
2
 
is applicable to
 
the immunogenic response 
rates and
 
gives the exact 95% confidence 
interval of the true response rate over possible number of res
ponses out of the 
5 and 1
2
 
subjects. 
 
6.3.3
 
Power for Comparison
 
As exploratory analyses, we 
will 
conduct pairwise comparisons between 
Group
s
 
2A, 2B, 2C, and 
2D
 
of the 
study 
for 
possible
 
difference
s
 
in immunogenicity
; 
a simple comparison on the positive 
response rate will be used. 
Table 6
-
3
 
gives the power of Fisher
’s
 
exact test to compare 
the
 
schedules over a range of possible response rates. It indicates that a compari
son between t
he
 
groups is not pow
ered by the study design with 1
2
 
samples per group.
 
Table 6
-
3: Power to Detect Difference in Response Rates between 
Any 
Group
 
by Fisher’s 
Exact Test, 
Where Both Groups are 
of Size n=
1
2
 
 
 
Group 
Y
 
(N=
1
2
)
 
Group 
Z
 
(N=1
2
)
 
 
0.1
 
0.2
 
0.3
 
0.4
 
0.5
 
0.6
 
0.1
 
 
2
 
9
 
23
 
42
 
64
 
0.2
 
2
 
 
3
 
9
 
2
1
 
39
 
0.3
 
9
 
3
 
 
4
 
9
 
2
1
 
0.4
 
23
 
9
 
4
 
 
4
 
10
 
0.5
 
42
 
2
1
 
9
 
4
 
 
4
 
0.6
 
64
 
39
 
2
1
 
10
 
4
 
 
 
S
TATISTICAL 
A
NALYSIS 
 
All statistical analyses will be performed using Statistical Analysis System (SAS), R, or 
S
-
Plus 
statistical software.
 
No formal multiple comparison adjustments will 
be employed
 
for safety 
endpoints or secondary endpoints.
 
6.4.1
 
Analysis Variables
 
The analysis variables
 
consist of baseline variables 
and 
safety
 
variables for primary and 
secondary objective analyses
.
 
6.4.2
 
Baseline Demographics
 
Baseline characteristics including demographics and laboratory measurements will be 
summarized using descriptive statistics
.
 
6.4.3
 
Safety Analysis
 
6.5.3.1 Reactogenicity
 
The number an
d percentage of participants experiencing each type of reactogenicity sign or 
symptom will be tabulated by severity. For a given sign or symptom, each participant’s 
reactogenicity will be counted once under the maximum severity for all assessments.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
32
 
of 
54
 
6.5.3.2
 
Adverse 
Events
 
AEs
 
are coded into Medical Dictionary for Regulatory Activities (MedDRA) preferred terms. 
The number and percentages of participants experiencing each specific 
AE
 
will 
be tabulated
 
by 
severity and relationship to treatment. For the calculat
ions in these tables, each participant’s 
AE
 
will 
be counted
 
once under the maximum severity or strongest recorded causal relationship to 
treatment.
 
A complete listing of 
AEs
 
for each participant will provide details including severity, 
relationship to trea
tment, onset, 
duration
 
and outcome.
 
6.5.3.3 Local Laboratory Values
 
Boxplots
, violin plots, or beeswarm plots 
of local laboratory values will be generated for baseline 
values 
and for
 
values measured 
during the course of
 
the study. Each plot will show the 1
st 
quartile, the median, and the 3rd quartile. Outliers, or values outside the boxplot, will also be 
plotted. If appropriate, horizontal lines representing boundaries for abnormal values will 
be 
plotted
.
 
6.4.4
 
Immunogenicity 
Analysis
 
The statistical analysis for
 
immunogenicity will employ the intent
-
to
-
treat principle whereby all 
data from enrolled subjects will 
be analyzed
 
according to the group assignment. However, if 
during immune assessment on stored samples, a subject is found to have a positive antibody 
res
ponse at baseline, the vaccine immune responses assessment for these subjects will not be 
included in the final immunogenicity analysis. If needed, a per
-
protocol analysis will 
be 
performed
 
as secondary analysis where subjects will be analyzed according to
 
their actual 
vaccination scheme if it is different from the assigned or up to the last visit in the study if there 
are early dropouts. 
The study is not designed to power the comparison in immune responses 
between vaccine dosages.
 
If assay data are qualitative (i.e., positive or 
negative)
 
then analyses will be performed by 
tabulating the frequency of positive response for each assay at each time point that 
an assessment
 
is performed
. Binomial response rates will 
be presented
 
with th
eir corresponding exact 95% 
confidence interval estimates.
 
Some immunologic assays have underlying continuous or count
-
type readout that 
is often 
dichotomized
 
into responder/
non
-
responder
 
categories. For these assays, graphical and tabular 
summaries of the
 
underlying distributions will 
be made
. These summaries may be performed on 
transformed data (e.g., log transformation) 
for ease of interpretation.
 
6.4.5
 
Missing Data
 
Missing responses will be assumed to be missing completely at random. Analyses will include 
all
 
samples available at each study 
time
 
point
.
 
Based on experience from previous trials, we 
expect missing data to be rare. Regardless, in the event of missing data, we will report the 
occurrence and extent of missingness. We will also provide plausible expl
anations for the 
missingness mechanism, should such information be available.
 
6.4.6
 
Interim Analyses
 
Safety Reviews: 
The PSRT will review safety data routinely throughout the study. The study 
will utilize both electronic database features and reviews by designat
ed safety review personnel 
to identify 
in a timely manner
 
if any of the safety pause rules of the study 
are met
. 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
33
 
of 
54
 
Immunogenicity Review: 
 
A
nalyses of immunogenicity may 
be performed
 
when 
pseudo
-
neutralization
 
assay of samples
 
collected 
2 weeks after 
each vaccination
 
are conducted
.
 
This may
 
occur 
prior to
 
completion of safety follow
-
up visits or collection of data for secondary and 
exploratory immunogenicity endpoints
.
 
Such an analysis would constitute the final analysis for 
the primary immunogenicity 
endpoint, so sample siz
e adjustments are not required.
 
Reports 
providing results by study group may be provided to VRC solely for the purpose of informing 
decisions related to future trials 
in a timely manner
. The results should in no way influence the 
con
duct of the 
VRC 321
 
trial 
in terms of
 
early termination or later safety or immunogenicity 
endpoint assessments. Analyses of secondary and exploratory immunogenicity assays may also 
be performed
 
as data become available.
 
 
PHARMACY
 
AND ADMINISTRATION P
ROCEDUR
ES 
 
T
he study g
roups and study agent dosing schedule 
are shown
 
in
 
Table 
1
 
in 
Section 
4
. 
Refer to 
the I
B
 
for further information about the 
investigational 
study 
products
.  
 
 
S
TUDY 
P
RODUCT
 
The study includes 
one 
investigational 
vaccine
 
described as follows:
 
•
 
VRC
-
FLUNPF099
-
00
-
VP
 
at 
180 
mcg/mL.
 
Vials contain
 
0.7
 
± 0.1 mL 
of
 
a c
lear, 
c
olorless
, isotonic buffered (pH=7.2) 
sterile
 
solution
.
 
The formulation buffer consists of 
20mM Sodium P
hosphate, 100mM Sodium 
Chloride
,
 
5% Sucrose
, and 0.01% PF
-
68
. 
Vials are intended for
 
single use only 
and do not contain a preservative. 
Vials must not be 
refrozen or reused after thawing.
 
 
•
 
VRC
-
PBSPLA043
-
00
-
VP (PBS), diluent, is a 
clear, colorless, sterile solution at pH 7.2, 
aseptically filled 
to a volume of 
1.2 mL in a 3 mL glass vial
. Vials are intended
 
for single 
use only and do not contain preservative
. Vials must not be refrozen or reused after 
thawing.
 
 
S
TUDY 
P
RODUCT
 
P
RESENTATION
 
AND 
S
TORAGE
 
7.2.1
 
Study 
Product 
Labels
 
At the time of study product delivery to the pharmacy, labels on study products VRC
-
FLUNPF099
-
00
-
VP and VRC
-
PBSPLA043
-
00
-
VP 
will have specific product information 
(e.g., 
product description, VRC product number, lot number, fill volume, concentration, fill 
date, 
storage condition). Labels will contain an Investigational Use Statement (“Limited by Federal 
Law to Investigational Use”) and manufacturer information.
 
7.2.2
 
Study 
Product
 
Storage
 
VRC
-
FLUNPF099
-
00
-
VP
 
(H1ssF_3928)
: 
V
ials 
will be shipped within the recommen
ded 
temperature range using appropriate shipping configurations to the study pharmacist
 
or designee
.
 
Vials of vaccine 
are stored
 
until use at
 
-
35
°
C
 
to
 
-
15°C
 
in a qualified,
 
continuously monitored, 
temperature
-
controlled freezer. As freezer temperatures may
 
fluctuate, a temperature range of 
-
45°C to 
-
10°C is acceptable. Storage 
below 
-
45ºC is not permitted because of the stopper 
limitation.
 
VRC
-
PBSPLA043
-
00
-
VP
 
(PBS)
: Vials are stored until use at the target temperature of 
-
35°C to 
-
15°C in a qualified, continuously monitored, temperature
-
controlled freezer. As freezer 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
34
 
of 
54
 
temperatures may fluctuate, a temperature range of 
-
45°C to 
-
10°C is acceptable based upon 
historic 
stability data from studies of similar products.
 
7.2.3
 
Temperature excursions 
 
If deviations in storage temperature occur from the normal allowance for the pharmacy freezer, 
the site pharmacist 
or designee 
must report the storage temperature excursion promptly t
o the PI 
and IND 
Sponsor
. The excursion must be evaluated and 
investigated,
 
and action must be taken to 
restore and maintain the desired temperature limits. Pending the outcome of the investigation, the 
IND 
Sponsor 
will notify the pharmacist if continued c
linical use of the product is acceptable.
 
 
P
REPARATION OF 
S
TUDY 
P
RODUCT
S
 
FOR 
I
NJECTION 
 
This section describes how the site pharmacist will prepare study injections. 
Clinician 
instructions on how to select an arm and administer an injection are in 
Section 
4.2.5
.
 
R
efer to the 
group assignment for the study subject to 
prepare the correct dose
. 
 
For all study groups, the prepared syringe
 
must
 
be labeled
 
with the subject identifier and the date 
and time
 
after which the preparation may not be used. 
Filled syringes should be kept at room 
temperature and out of direct sunlight until product 
administration
. 
All injections must be 
administered within 
4
 
hours after removing the vaccine vial from the freezer.
 
7.3.1
 
P
reparation of 
VRC
-
FLUNPF099
-
00
-
VP
 
for
 
Needle and Syringe 
Administration
 
S
ubjects 
will
 
receive the vaccine via 
needle and syringe
 
injection
. T
he 
following instructions 
apply
 
for 
VRC
-
FLUNPF099
-
00
-
VP
 
preparation
. More information on vaccine 
preparation is 
available in the IB.
 
Group 1
 
(
20 mcg
)
:
 
1.
 
Thaw 1 vial of 
H1ssF_3928
 
at room temperature 
(15 to 30º C) 
until all ice crystals have 
melted.  Swirl gently to mix.
 
2.
 
Thaw 1 vial of PBS diluent at room temperature 
(15 to 30º C) 
until all ice crystals have 
melted.  Swirl gently to mix.
 
3.
 
Withdraw 0.11
 
mL of 
H1ssF_3928
 
into the syringe.
 
4.
 
Withdraw 0.2
 
mL of PBS into the 
same 
syringe.
 
5.
 
Invert syringe 5x to mix.
 
Group 2
A, 
Group 
2
B, Group
 
2
C, 
and 
Group 
2
D
 
(
60 mcg
)
:
 
1.
 
Thaw 1 vial of 
H1ssF_3928
 
at room temperature 
(15 to 30º C)
 
until all ice crystals have 
melted.  Swirl gently to mix.
 
2.
 
Withdraw 0.33
 
mL of 
H1ssF_3928
 
into the syringe.
 
7.3.2
 
Administration of Injections
 
Refer to 
Section 4.2.5
. Product labeling and IM injection procedures will be performed 
consistent with institutional policies and standard procedures.
 
 
S
TUDY 
P
RODUCT 
A
CCOUNTABILITY
 
7.4.1
 
Documentation
 
The study pharmacist 
or designee 
will be responsible for maintaining an accurate record of the 
codes, inventory, and an accountability record of 
the investigational study products
 
supplies for 
this study. Electronic documentation as well as paper copies wi
ll be used.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
35
 
of 
54
 
7.4.2
 
Disposition
 
The empty vials
,
 
the 
partially
-
used
 
vial
s
, and any unused, unopened vial that has been removed 
from freezer 
will be discarded 
on the 
same 
day 
as removal from freezer 
in a biohazard 
containment bag and incinerated or autoclaved 
per f
acility policy
. Any unopened vials that 
remain at the end of the study will be discarded 
or returned 
at the discretion of the VRC in 
accordance with policies that apply to investigational products. Partially used vials or expired 
prepared doses cannot be a
dministered to other subjects nor used for 
in vitro
 
experimental 
studies and will be discarded as indicated above.
 
 
HUMAN SUBJECT PROTEC
TIONS AND ETHICAL OB
LIGATIONS
 
This research study will 
be conducted
 
in compliance with the protocol, 
International Co
unci
l
 
f
o
r
 
Harmoni
s
ation Good Clinical Practices (ICH
-
GCP) guidance, and all applicable regulatory 
requirements
.
 
 
I
NSTITUTIONAL 
R
EVIEW 
B
OARD
 
A copy of the protocol, 
ICF
, other written subject
-
facing 
information, and any advertising 
material will be submitted to the NIAID IRB for written approval 
prior to
 
use
.
 
The 
PI 
must submit and, where necessary, obtain approval from the IRB for all subsequent 
protocol amendments and changes to the ICF. The 
PI 
will notify the IRB of 
events that occur on 
study
 
as described in Section 
5.4
.
 
The investigator will be responsible for obtaining IRB approval of the 
annual
 
Continuing Review 
throughout the duration of the 
study.
 
 
S
UBJECT 
I
DENTIFICATION AND 
E
NROLLMENT OF 
S
TUDY 
P
ARTICIPANTS 
 
Study subjects will 
be recruited
 
through on
-
site and off
-
site advertising done for the screening 
protocol, VRC 500 (11
-
I
-
0164). All study activities will be carried out at the NIH CC. 
Effort
 
will 
be made to include women and minorities in proportions simil
ar to that of the community from 
which they 
are recruited
.
 
8.2.1
 
Participation of Children
 
Children are not eligible to participate in this clinical trial because the investigational vaccine
 
has 
not 
been previously evaluated
 
in adults. If the product 
is assessed
 
as safe and immunogenic, 
other protocols designed for children may 
be conducted
 
in the future.
 
8.2.2
 
Participation of NIH Employees
 
NIH employees and members of their immediate families may participate in this protocol. 
NIH 
staff may be
 
a
 
vulnerable class of su
bjects. 
The VRC will follow the Guidelines for the Inclusion 
of Employees in NIH Research Studies and will give each employee a copy of the “NIH 
Information Sheet on Employee Research Participation” and a copy of the “Leave Policy for 
NIH Employees Partici
pating in NIH Medical Research studies.”
 
Neither participation nor refusal to participate will have an effect, either beneficial or adverse, on 
the participant’s employment or work situation. The NIH information sheet regarding NIH 
employee research partic
ipation will 
be distributed
 
to all potential subjects who are NIH 
employees. The employee subject’s privacy and confidentiality will 
be preserved
 
in accordance 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
36
 
of 
54
 
with
 
NIH CC and NIAID policies. For NIH employee subjects, consent will 
be obtained
 
by an 
indivi
dual who is independent of the employee’s team. If the individual obtaining consent is a 
co
-
worker to the subject, independent monitoring of the consent process will be included 
through
 
the Bioethics Consultation Service. Protocol study staff will be train
ed on obtaining potentially 
sensitive and private information from co
-
workers or subordinates.
 
 
I
NFORMED 
C
ONSENT
 
The study 
ICF
 
describes the investigational product to be used and all aspects involved in 
protocol participation.
 
Before a subject’s participat
ion in the study, the investigators 
must
 
obtain written informed 
consent from the subject, after adequate explanation of the aims, methods, anticipated benefits, 
and potential hazards of the study and before any protocol
-
specific procedures or study 
produc
ts 
are administered.
 
An IRB
-
approved 
AoU
, intended to assist in the evaluation of the subject’s understanding of this 
study, is administered as part of the consent process.
 
The acquisition of informed consent will be documented in the subject’s medical records, as 
required by 21 CFR 312.62, and the 
ICF
 
will be signed and personally dated by the subject and 
by the person who conducted the informed consent discussion. The origi
nal
,
 
signed 
ICF
 
will 
be 
placed
 
in the medical 
record
 
and a copy of the signed ICF will 
be provided
 
to the subject.
 
 
S
UBJECT 
C
ONFIDENTIALITY
 
The investigator must ensure that the subject’s anonymity is 
maintained and
 
will ensure that no 
information identifyi
ng the subject will 
be released
 
to any unauthorized party. Subjects will not 
be identified
 
in any reports on this study. All records will be kept confidential to the extent 
provided by federal, state and local law. Medical records 
are made
 
available for re
view when 
required by the FDA or other authorized users, such as the vaccine manufacturer, only under the 
guidelines set by the Federal Privacy Act. Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are im
portant to the evaluation of the 
study. The investigator is obligated to inform the subjects that the 
above
-
named
 
representatives 
will review their study
-
related records without violating the confidentiality of the subjects. 
Stored study research samples a
re labeled by a code (such as a number) that only the study team 
can link to the subject. The requirement to maintain subject confidentiality 
is 
discussed
 
in the 
study ICF.
 
 
R
ISKS AND 
B
ENEFITS 
 
8.5.1
 
Risks
 
of the 
VRC
-
FLUNPF099
-
00
-
VP
 
vaccine
 
This is
 
the first stud
y in humans of 
th
e
 
investigational 
vaccine, 
VRC
-
FLUNPF099
-
00
-
VP
. T
h
is
 
product 
is derived
 
from 
H. pylori
 
f
erritin and not human ferritin, for this 
reason
 
i
t is not expected 
to 
interfere with iron storage
, 
transport or iron serum levels
 
[
18
]
.
 
Potential side effects resulting from 
IM 
injection include stinging, arm discomfort, redness of the 
skin
 
or 
mild bruising at vaccine injection sites.  
 
Subjects may exhibit general signs and symptoms associated with 
administration
 
of a vaccine, 
including fever, chills, rash, aches and pains, nausea, headache, 
dizziness
 
and fatigue.  These 
side effects will be mo
nitored, but are 
generally
 
short term, mild to moderate severity and 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
37
 
of 
54
 
usually do not require treatment.
 
In 
a
nother 
VRC 
study 
of a similar 
ferritin 
vaccine
 
(VRC 316)
, 
only 
23.4% 
of 
participants
 
were 
noted to have occasional asymptomatic and self
-
limited chan
ges in laboratory tests such as 
mild 
leukocytosis
,
 
mild leukopenia
,
 
and mild increase in 
ALP
 
as 
of March
 
24, 2019
.
 
There may be other unknown side effects.
 
8.5.2
 
Risks of Specimen Collections
 
•
 
Blood drawing
:
 
The risks of blood sample collection are minimal and consist of mild 
discomfort at the sample collection site. The procedure 
may cause pain, bruising, 
fainting, and, rarely, infection at the site where the blood 
is taken
.
 
•
 
Apheresis
:
 
The procedure
 
may cause
 
pain, bruising, and discomfort in the arms w
h
ere the 
needles are placed. It may also cause chills, nausea, heartburn, mild muscle cramps and 
tingling sensation around the mouth or in the fingers, however this can usually be 
relieved by slowing or temporar
ily interrupting the 
apheresis
 
procedure
 
or taking a 
calcium containing antacid, such as Tums®. Other possible side effects are anxiety, 
vomiting and lightheadedness. Temporary lowering of the blood pressure may develop. 
There is the rare possibility of in
fection, fainting or seizure. Very rarely a nerve problem 
at the needle placement site may occur. Also, very rarely, a machine malfunction may 
occur, resulting in the loss of about one unit of blood. There may be additional risks of 
apheresis
 
that are unkn
own at this time.
 
•
 
Mucosa 
s
ample
s
:
 
Collection of samples by nasopharyngeal swabs rubbed over the 
mucosal surfaces may cause momentary discomfort and, in some cases, minor bleeding.
 
8.5.3
 
Risks of study vaccines on the fetus or nursing infant
 
We do not know the possible effects of the study vaccine on the fetus or nursing infant. Women 
of reproductive potential will be required to agree to use 
an effective method of 
birth control 
beginning 21 days 
prior to
 
enr
ollment and continuing through 
end 
of
 
study. 
 
Because this is a research study, women of reproductive potential will be tested for pregnancy 
prior to administration of each study injection and asked to notify the site immediately upon 
learning of a pregnancy during this study. In 
the
 
case o
f pregnancy, subjects will 
no longer 
receive additional vaccine 
but
 
will
 
continue to be followed for safety. 
R
esearch sample 
collections 
will 
be discontinued for pregnant wome
n
. 
The subject will be contacted to ask about 
the outcome of a pregnancy that beg
ins during the
 
study.
 
8.5.4
 
Risks of 
N
ew 
D
iagnoses
 
It is possible that the standard medical tests performed as part of this research protocol will result 
in new diagnoses. Depending upon the medical findings and consequences of being provided 
with the new 
medical information about health status, the study subject may view this aspect of 
study participation as either a risk or a benefit. Any such information will be shared and 
discussed with the subject and, if requested by the subject, will be forwarded to 
the subject’s 
primary health care provider for further workup and management.
 
8.5.5
 
Study Benefits 
 
Study subjects will not receive 
direct
 
health benefit from study participation. This protocol is not 
designed to provide treatment for any condition. Others may b
enefit from 
knowledge
 
gained in 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
38
 
of 
54
 
this study that may aid in the development of an H
1
 
(or universal) influenza virus vaccine. 
The
 
investigational vaccine 
is 
not
 
expected to provide protection from influenza.
 
 
P
LAN FOR 
U
SE AND 
S
TORAGE OF 
B
IOLOGICAL 
S
AMPLES
 
The
 
plan for use and storage of biological
 
samples from this protocol 
is 
as 
outlined 
in the 
following sections
.
 
8.6.1
 
U
se of 
S
amples
, 
S
pecimens
 
and D
ata
 
Samples, 
specimens
 
and data collected under this protocol may be used to conduct protocol
 
related safety and 
immune response evaluations, exploratory laboratory evaluations related to the 
type of infection the study product was designed to prevent, exploratory laboratory evaluations 
related to vaccine or infectious disease research in general and for research ass
ay validation.
 
Genetic testing may 
be performed
 
in accordance with
 
the genetic testing information that 
is
 
included
 
in the study ICF. HLA testing may 
be done
 
in association with identifying factors 
linked with the immune response development or progression
 
of infections. 
 
Additional optional genetic testing, including 
t
ranscriptome
 
sequencing
 
may 
be done
 
on 
collected specimens 
in an effort to
 
assess
 
the expression of genes involved in the immune 
response
 
to vaccination.
 
 
Results of genetic testing may have 
psychological implications for patients such as revelations 
regarding future health risks, incurable conditions, 
and/or
 
information contradictory to stated 
biological relationships. Genetics counseling and advice will be available from the NIH to help 
subj
ects at all study sites with the implications of findings, where appropriate. 
 
Following genetic testing, the data will be shared in a controlled
-
access public database for other 
investigators to benefit from it (e.g. the Database of Genotypes and Phenotyp
es dbGAP).
 
However
,
 
no personal identifiable information will be shared in this process as the results will 
only 
be shared
 
with a code.
 
Other 
optional analysis, including proteome, lipidome, metabolome, 
and exosome may be done on collected specimens to eva
luate some proteins, lipids, 
metabolites, 
and low molecular weight molecules involved in the immune response to vaccination. 
 
8.6.2
 
Storage and Tracking of Blood S
amples
 
and
 
Other S
pecimens
 
All of the stored study research samples are labeled by a code
 
that only the site can link to the 
subject. Samples 
are stored
 
at the 
VIP
, Gaithersburg, MD or VRC 
l
aboratories in Building 40, 
Bethesda, MD, which are both secure facilities with limited access. Data will be kept in 
password
-
protected computers. Only inv
estigators or their designees will have access to the 
samples and data. Samples will be tracked in the Laboratory Information Management System 
(LIMS) database or using another software designed for this purpose (e.g., Freezerworks).
 
8.6.3
 
Disposition of S
amples
, 
S
pecimens
 
and D
ata at
 
C
ompletion of the 
P
rotocol
 
 
In the future, other investigators (both at NIH and outside) may wish to study these samp
les 
and/or
 
data. I
RB approval must be sought prior to any sharing of samples
. 
A
ny clinical 
information shared about
 
those samples would similar
ly require prior IRB approval. 
The 
research use of stored, unlinked or unidentified samples may be exempt from the need for 
prospective IRB review and approval.
 
Exemption requests will be submitted in writing to the 
NIH Office o
f Human Subjects Research, which is authorized to determine whether a research 
activity is exempt.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
39
 
of 
54
 
At the time of protocol termination, samples will remain in the 
VIP
 
facility or VRC laboratories 
or, after IRB approval, transferred to another repository. 
Regulatory oversight of the stored 
samples and data may be transferred to a stored samples protocol as part of the
 
IRB
-
approved 
termination plan.
 
Data will be 
archived by the VRC in compliance with requirements for 
retention of research records, or after IRB and study sponsor approval, it may be either destroyed 
or transferred to another repository.
 
8.6.4
 
L
oss or 
D
estruction of 
S
amples
, S
pecimens
 
or D
ata
 
The NIH Intra
mural Protocol 
Deviation
 
definition related to loss of or destruction of samples 
or 
data 
will be followed
.
 
Any loss or unanticipated destruction of samples (for example, due to 
freezer malfunction) or data (for example, misplacing a printout of data with i
dentifiers) 
that 
compromises the scientific integrity of the study 
will be reported to the IRB
 
in accordance with 
institutional policies
.
 
The PI will also notify the IRB if the decision is made to destroy the 
remaining samples.
 
 
C
OMPENSATION
 
Subjects will 
b
e compensated
 
for time and inconvenience in accordance with the standards for 
compensation of the 
NIH 
Clinic
al Research Volunteer Program. 
The compensation per visit will 
be $275 for visits that include injections and $175 for clinic visits 
that 
include a blood draw. 
Any 
visit that includes mucosal sample collection will 
result in
 
an additional $50
 
in compensation
.
 
The compensation for any clinic visit that does not include a blood draw or 
mucosal sample 
collection wil
l be $75
. 
The c
ompensation fo
r 
timely 
completion of 
the 
electronic 
diary card will 
be $25.
 
Compensation will be $250 
for 
apheresis
,
 
i
f
 
performed. 
The total compensation for the 
subject is based on the number of study clinic visits, injections completed and if optional 
research bl
ood c
ollections are performed. 
 
Subjects will receive compensation
 
by direct deposit within 
approximately 
1 or 
2 weeks after 
each completed visit.
 
Compensation may need to be reported to the Internal Revenue Service 
(IRS) as taxable income.
 
The approximate tota
l compensation is as follows:
 
 
Group
 
Without 
Apheresis
 
With 
Apheresis
 
Group 1
 
$1,8
7
5
 
NA
 
Group 
2
A
 
Group 
2
B
 
Group 
2
C 
 
Group 
2
D
 
$2,
525
 
$2,
600
 
 
S
AFETY 
M
ONITORING
 
 
8.8.1
 
Protocol Safety Review Team
 
Close cooperation between the designated members of the Protocol Team will occur to evaluate 
and respond to individual 
AEs
 
in a timely manner
. 
The VRC designated Safety Officer for the 
day conducts a daily safety review of clinical data per VRC Standard Operating Procedures. 
The 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
40
 
of 
54
 
PSRT
, comprised of the 
P
I
, 
Associate Investigators, Study Coordinator, 
Protocol Specialist
s
,
 
and 
other Study C
linicians
,
 
will review the summary study safety data reports on a weekly basis 
through 4 weeks afte
r the last 
subject receives the final study injection.
 
After this time, the PSRT
 
will monitor the safety data reports on a monthly basis throug
h completion of the las
t 
study
 
visit.
  
 
 
ADMINISTRATIVE AND L
EGAL OBLIGATIONS
 
 
P
ROTOCOL 
A
MENDMENTS AND 
S
TUDY 
T
ERMINATION
 
Agreement from the 
PI 
must 
be obtained
 
for all amendments to the
 
protocol and the
 
informed 
consent document.
 
All study amendments will 
be submitted
 
to the IRB for approval.
 
T
he
 
VRC
,
 
NIAID IRB, Office of Human Research Protections, 
study 
P
I,
 
and 
FDA
 
reserve
s
 
the 
r
ight to terminate the study. 
The 
PI
 
will notify the IRB in writing of the study’s completion or 
early 
termination.
 
 
S
TUDY 
D
OCUMENTATION AND 
S
TORAGE
 
The 
PI
 
will maintain a list of appropriately qualified persons to whom trial duties have 
been 
delegated
.
 
Source documents are original documents, data, and records from which t
he subject’s data 
are 
obtained
.
 
These include but are not limited to hospital records, clinical and office charts, 
laboratory
 
and pharmacy records, 
and correspondence. 
 
The 
PI
 
and staff are responsible for maintaining a comprehensive and centralized filing system of 
all study
-
related (es
sential) documentation, suitable for inspection at any t
ime by representatives 
from the
 
V
RC
, IRB, FDA, 
and/or
 
applicable regulatory authorities. Elements include
 
but not 
limited to
:
 
•
 
Subject files containing completed informed consent forms, and supporting 
copies of 
source documentation (if kept)
 
•
 
Study files containing the protocol with all amendments, Investigator Brochures, copies 
of all correspondence with the IRB and 
VRC
 
In addition
, all 
original source
 
documentation must be maintained and be readily ava
ilable.
 
All essential documentation 
will 
be retained by the institution
 
for the same 
period of time
 
required for medical records retention. The FDA requires study records to 
be retained
 
for up to 
two years after marketing approval or refusal (21 CFR 312.62
).
 
No study document 
will
 
be 
destroyed
 
without prior written agreement between
 
the
 
VRC
 
and the 
PI
. 
 
 
D
ATA 
C
OLLECTION
,
 
D
ATA 
S
HARING
 
AND 
P
ROTOCOL 
M
ONITORING
 
9.3.1
 
Data Collection
 
Clinical research data will 
be collected
 
in a secure electronic 
web
-
based clinical 
data 
management system 
(CDMS) 
through a contract research organization, 
The 
E
mmes 
Company, 
LLC 
(Rockville, MD). Extracted data without patient identifiers will be sent to 
the
 
Protocol 
Statistician for statistical 
analysis.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
41
 
of 
54
 
9.3.2
 
Data Sharing Plan
 
Data generated in this study will be shared as de
-
identified data in the government
-
funded public 
repository, 
www.ClinicalTrials.gov
.  Data may be shared prior to publication at appr
oved public 
presentations or for collaborative development and will be shared at the time of publication or 
within 1 year 
of the primary completion date. 
 
9.3.3
 
Source Documents 
 
The site will maintain appropriate medical and research records for this trial, in 
compliance with 
ICH
-
GCP, regulatory and institutional requirements for the protection of confidentiality of 
subjects.
 
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary fo
r the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include but are not limited to medical records, 
laboratory reports, pharmacy records and other research records maintained for the clinical trial.
 
9.3.4
 
Proto
col Monitoring Plan
 
Site investigators will allow the study monitors, the NIAID IRB, and the FDA to inspect study 
documents (e.g., consent forms, drug distribution forms, and case report forms) and pertinent 
hospital or clinic records for 
confirmation of the study data.
 
Site visits by study monitors will 
be made
 
in accordance with
 
the study monitoring plan to 
monitor the following: study operations, the quality of data collected in the research records, the 
accuracy and timeliness of data e
ntered in the database, and to determine that all process and 
regulatory requirements 
are met
. Study monitoring visits will occur as defined by the IND 
Sponsor approved monitoring plan.
 
 
L
ANGUAGE
 
All written information and other material to be used by subj
ects and investigative staff must use 
vocabulary and language that are clearly understood
 
by the subject
. 
 
 
P
OLICY 
R
EGARDING 
R
ESEARCH
-
R
ELATED 
I
NJURIES
 
The 
NIH 
CC
 
will provide short
-
term medical care for any injury resulting from
 
participation in 
this research.
 
In general, the 
NIH
, the 
NIH CC
, or the 
U.S. 
Federal Government will provide no 
long
-
term medical care or financial compensation for research
-
related injuri
es.
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
42
 
of 
54
 
 
REFERENCES
 
1.
 
WHO. 
Influenza (Seasonal) Fact Sheet
. 2009; Available from: 
http://www.who.int/mediacentre/factsheets/fs211/en/index.html
.
 
2.
 
Meltzer, M.I., 
N.J. Cox, and K. Fukuda, 
The economic impact of pandemic influenza in 
the United States: priorities for intervention.
 
Emerg Infect Dis, 1999. 
5
(5): p. 659
-
71.
 
3.
 
Subbarao, K., B.R. Murphy, and A.S. Fauci, 
Development of effective vaccines against 
pandemic 
influenza.
 
Immunity, 2006. 
24
(1): p. 5
-
9.
 
4.
 
CDC. 
Types of Influenza Viruses
. 2014  4/15/2014]; Available from: 
http://www.cdc.gov/flu/about/viruses/types.htm
.
 
5.
 
Taubenberger, J.K. and J.C. Kash, 
Influenza virus evolution, host adaptation, and 
pandemic formation.
 
Cell Host Microbe, 2010. 
7
(6): p. 440
-
51.
 
6.
 
D C Wiley, a. and J.J. Skehel, 
The Structure and Function 
of the Hemagglutinin 
Membrane Glycoprotein of Influenza Virus.
 
Annual Review of Biochemistry, 1987. 
56
(1): p. 365
-
394.
 
7.
 
Ekiert, D.C., et al., 
Antibody recognition of a highly conserved influenza virus epitope.
 
Science, 2009. 
324
(5924): p. 246
-
51.
 
8.
 
Thro
sby, M., et al., 
Heterosubtypic neutralizing monoclonal antibodies cross
-
protective 
against H5N1 and H1N1 recovered from human IgM+ memory B cells.
 
PLoS One, 2008. 
3
(12): p. e3942.
 
9.
 
Corti, D., et al., 
A neutralizing antibody selected from plasma cells th
at binds to group 1 
and group 2 influenza A hemagglutinins.
 
Science, 2011. 
333
(6044): p. 850
-
6.
 
10.
 
Harris, A.K., et al., 
Structure and accessibility of HA trimers on intact 2009 H1N1 
pandemic influenza virus to stem region
-
specific neutralizing antibodies
.
 
Proc Natl Acad 
Sci U S A, 2013. 
110
(12): p. 4592
-
7.
 
11.
 
Tripp, R.A. and S.M. Tompkins, 
Virus
-
vectored influenza virus vaccines.
 
Viruses, 2014. 
6
(8): p. 3055
-
79.
 
12.
 
CDC. 
Vaccine Effectiveness 
-
 
How Well Does the Flu Vaccine Work?
 
2016 11/14/2016; 
Availab
le from: 
https://www.cdc.gov/flu/about/qa/vaccineeffect.htm
.
 
13.
 
Lambert, L.C. and A.S. Fauci, 
Influenza vaccines for the future.
 
N Engl J Med, 2010. 
363
(21): p. 2036
-
44.
 
14.
 
Krammer, F. an
d P. Palese, 
Advances in the development of influenza virus vaccines.
 
Nat 
Rev Drug Discov, 2015. 
14
(3): p. 167
-
82.
 
15.
 
Neuzil, K.M. and R.A. Bright, 
Influenza vaccine manufacture: keeping up with change.
 
J 
Infect Dis, 2009. 
200
(6): p. 835
-
7.
 
16.
 
Yassine, H
.M., et al., 
Hemagglutinin
-
stem nanoparticles generate heterosubtypic 
influenza protection.
 
Nat Med, 2015. 
21
(9): p. 1065
-
70.
 
17.
 
Bai, L., et al., 
Genome
-
wide comparison of ferritin family from Archaea, Bacteria, 
Eukarya, and Viruses: its distribution, cha
racteristic motif, and phylogenetic 
relationship.
 
Naturwissenschaften, 2015. 
102
(9
-
10): p. 64.
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
43
 
of 
54
 
18.
 
Kanekiyo, M., et al., 
Self
-
assembling influenza nanoparticle vaccines elicit broadly 
neutralizing H1N1 antibodies.
 
Nature, 2013. 
499
(7456): p. 102
-
6.
 
19.
 
Yamashita, I., K. Iwahori, and S. Kumagai, 
Ferritin in the field of nanodevices.
 
Biochim 
Biophys Acta, 2010. 
1800
(8): p. 846
-
57.
 
20.
 
Zhao, L., et al., 
Nanoparticle vaccines.
 
Vaccine, 2014. 
32
(3): p. 327
-
37.
 
21.
 
Krammer, F., P. Palese, and J. Steel, 
Advance
s in universal influenza virus vaccine design 
and antibody mediated therapies based on conserved regions of the hemagglutinin.
 
Curr 
Top Microbiol Immunol, 2015. 
386
: p. 301
-
21.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
44
 
of 
54
 
APPENDIX 
I
: SCHEDULE OF EVALUA
TIONS
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
45
 
of 
54
 
 
VRC
 
500
 
VRC
 
 
321
 
Schedule
 
of
 
Evaluations: 
Group
 
1
 
Visit
 
Number
 
*01
 
02
 
02A
 
03
 
04
 
05
 
06
 
0
7
 
0
9
 
1
1
 
1
2
 
1
3
 
Week of
 
Study
 
-
4
 
to 0
 
W0
 
W1
 
W1
 
W2
 
W4
 
W12
 
W16
 
W18
 
W28
 
W40
 
W52
 
Day 
of
 
Study
 
-
28 to 0
 
1
D0
 
D1
 
D6
 
D14
 
D28
 
D84
 
D112
 
D126
 
D196
 
D280
 
D364
 
Clinical
 
Tube
 
 
 
 
 
 
 
 
 
 
 
 
 
*VRC
 
500
 
Screening
 
Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
VRC 321
 
AoU; Consent
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
2
Physical 
exam
 
for
 
eligibility,
 
height
 
/weight/ vitals
 
at
 
screening; 
vital 
signs and
 
targeted 
exam
 
(as
 
needed)
 
other visits.
 
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Medical
 
history
 
targeted 
to
 
eligibility at
 
screening;
 
then
 
interim 
medical
 
history
 
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
3
Study
 
Product Administration:
 
Group
 
1
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
Phone 
evaluation
 
(clinic visit as
 
needed)
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
Begin 
diary 
card
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
4
Pregnancy
 
test: urine
 
or serum
 
 
X
 
X
 
 
 
 
X
 
 
 
 
 
X
 
X
 
4
Pregnancy
 
prevention counseling/
 
Reproductive 
Information 
Form
 
 
X
 
X
 
 
 
 
X
 
 
 
 
 
X
 
X
 
CBC with 
differential
 
EDTA
 
3
 
3
 
 
 
3
 
3
 
 
 
 
 
3
 
3
 
Iron and serum ferritin
 
 
X
 
 
 
 
 
X
 
 
 
 
 
 
 
Total 
bilirubin,
 
AST, ALT,
 
and
 
ALP 
 
GLT
 
4
 
4
 
 
 
4
 
4
 
 
 
 
 
4
 
4
 
Creatinine
 
 
X
 
X
 
 
 
X
 
 
 
 
 
 
 
 
5
HLA
 
type
 
EDTA
 
 
 
 
 
 
 
 
 
 
20
 
 
 
HIV 
Ab/Ag Combo 
(other
 
tests,
 
if 
needed)
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
Research
 
Samples
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. pylori 
ferritin antibody 
and 
human 
ferritin 
antibody
 
SST
 
X
 
 
 
 
 
X
 
 
 
 
 
 
 
Serum
 
 
SST
 
32
 
16
 
 
16
 
16
 
16
 
16
 
16
 
16
 
16
 
16
 
16
 
PBMC and 
plasma
 
 
EDTA
 
80
 
80
 
 
6
80
 
80
 
80
 
80
 
80
 
40
 
80
 
80
 
80
 
Daily Volume 
(mL)
 
 
12
2
 
103
 
0
 
96
 
103
 
103
 
96
 
96
 
56
 
116
 
103
 
103
 
Max. 
Cumulative Volume
 
(mL)
 
 
12
2
 
22
5
 
22
5
 
32
1
 
42
4
 
5
2
7
 
62
3
 
7
19
 
7
7
5
 
89
1
 
99
4
 
1,
09
7
 
* 
VRC
 
500:
 
S
creening evaluations
 
must
 
be no more
 
than
 
28
 
days
 
prior
 
to Day
 
0 
to
 
be
 
used for
 
eligibility
 
(
negative 
pregnancy test
 
from
 
Day
 
0
 
must
 
be
 
used
 
for 
eligibility).
 
If
 
clinical
 
assessment
 
on
 
Day
 
0
 
suggests 
significant
 
changes
 
may have
 
occurred since
 
screening,
 
then
 
physical
 
examination
 
& 
laboratory studies
 
done on Day
 
0
 
are
 
used
 
for 
eligibility.
 
1
 
Day
 
0=day of
 
enrollment
 
and
 
first
 
vaccine
 
injection.
 
Day 
0
 
evaluations
 
prior
 
to
 
first
 
injection
 
are the baseline
 
for
 
assessing adverse
 
events
 
subsequently.
 
2
 
Screening visit
 
includes
 
physical exam with
 
vital
 
signs. At
 
other visits,
 
physical
 
exam
 
is
 
done
 
if
 
indicated. Otherwise 
only
 
blood
 
pressure (BP),
 
pulse,
 
temperature
, and respiration
 
are
 
required.
 
3 
Study
 
Product Administration
:
 
Group 
1
 
will
 
receive 
H1ssF_3928
 
20
 
mcg IM at Day 0.
 
Complete
 
post
 
vaccination
 
evaluations
 
(BP, pulse,
 
temperature,
 
respiration
 
and
 
injection
 
site
 
assessment)
 
at
 
1 
hour
 
or
 
longer
 
after
 
injection.
 
4
 
Negative
 
pregnancy
 
test
 
results
 
must
 
be
 
confirmed for
 
women of reproductive
 
potential
 
prior
 
to
 
each
 
study
 
injection
.
 
5 
HLA
 
type blood sample
 
is
 
collected
 
once at any
 
time
-
point
 
in
 
the
 
study
 
and
 
is
 
shown
 
as
 
a
 
Visit
 
0
5
 
evaluation
 
for
 
convenience;
 
however,
 
if
 
HLA
 
type is
 
already
 
available
 
in the
 
medical
 
record,
 
it
 
does
 
not
 
need
 
to
 
be
 
repeated.
 
HLA
 
type
 
may also
 
be obtained
 
from
 
a 
frozen sample.
 
6
 
Visit 03: Two tubes of PBMC collected in EDTA tubes will be sent to Building 40, while the remainder of the blood collected w
ill be sent to 
VIP
VITL.
 
Visit windows:
 
Schedule Visits
 
02A 
-
 
1
3
 
with
 
respect
 
to Day 0 
per 
the following 
visit
 
windows:
 
Visit
 
02A 
(+1 day). Visit 03
 
(±1 day). Visits
 
04
, 05
,
 
0
9
 
(±2 days). Visits
 
0
7
 
(± 
7
 
days).
 
Visit
 
0
6
 
(±
14
 
days)
. Visit
s
 
11,
 
1
2
 
and 1
3
 
(± 14 days). 
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
46
 
of 
54
 
 
VRC
 
500
 
VRC
 
 
321
 
Schedule
 
of
 
Evaluations: 
Groups
 
2A, 2
B, 
2
C,
 
2D
 
Visit
 
Number
 
*01
 
02
 
02A
 
03
 
04
 
05
 
06
 
07
 
07A
 
08
 
0
9
 
1
0
 
1
1
 
1
2
 
13
 
14
 
Week of
 
Study
 
-
4 to 0
 
W0
 
W1
 
W1
 
W2
 
W4
 
W12
 
W16
 
W17
 
W17
 
W18
 
W20
 
W28
 
W40
 
W
52
 
W68
 
Day 
of
 
Study
 
-
28 
to 0
 
1
D0
 
D
1
 
D6
 
D14
 
D28
 
D84
 
D112
 
D113
 
D118
 
D126
 
D140
 
D196
 
D280
 
D364
 
D476
 
Clinical
 
Tube
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*VRC
 
500
 
Screening
 
Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 321
 
AoU; Consent
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
Physical 
exam
 
for
 
eligibility,
 
height
 
/weight/ vitals
 
at
 
screening; vital 
signs and
 
targeted 
exam
 
(as
 
needed)
 
other visits.
 
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
X
 
Medical
 
history
 
targeted 
to
 
eligibility at
 
screening;
 
then
 
interim medical
 
history
 
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
X
 
3
Study
 
Product Administration:
 
Group
 
2A
-
2D
 
 
 
X
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
 
Phone 
evaluation
 
(clinic visit as
 
needed)
 
 
 
 
X
 
 
 
 
 
 
X
 
 
 
 
 
 
 
 
Begin 
diary 
card
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
Pregnancy test:
 
urine or
 
serum
 
 
X
 
X
 
 
 
 
X
 
 
X
 
 
 
8
[
X
]
 
X
 
 
X
 
X
 
X
 
4
Pregnancy
 
prevention counseling/
 
Reproductive 
Information 
Form
 
 
X
 
X
 
 
 
 
X
 
 
X
 
 
 
8
[
X
]
 
X
 
 
X
 
X
 
X
 
CBC with 
differential
 
EDTA
 
3
 
3
 
 
 
3
 
3
 
 
3
 
 
 
 
3
 
 
3
 
3
 
3
 
Iron
 
and serum ferritin
 
 
X
 
 
 
 
 
 
 
X
 
 
 
 
X
 
 
 
 
 
Total 
bilirubin,
 
AST, ALT,
 
and
 
ALP
 
GLT
 
4
 
4
 
 
 
4
 
4
 
 
4
 
 
 
 
4
 
 
4
 
4
 
4
 
Creatinine
 
 
X
 
X
 
 
 
X
 
 
 
 
 
 
 
X
 
 
 
 
 
5
HLA
 
type
 
EDTA
 
 
 
 
 
 
 
 
 
 
 
 
 
20
 
 
 
 
HIV 
Ab/Ag Combo 
(other
 
tests,
 
if 
needed)
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research
 
Samples
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. pylori 
ferritin antibody 
and
 
h
uman ferritin 
antibody
 
SST
 
X
 
 
 
 
 
X
 
 
 
 
 
 
X
 
 
 
 
 
Serum
 
 
SST
 
32
 
16
 
 
16
 
16
 
16
 
16
 
16
 
 
16
 
16
 
16
 
16
 
16
 
16
 
16
 
PBMC and 
plasma
 
 
EDTA
 
80
 
80
 
 
6
80
 
80
 
80
 
80
 
80
 
 
80
 
7
120 or 
Apheresis (6)
 
80
 
80
 
80
 
80
 
80
 
Daily Volume 
(mL)
 
 
12
2
 
103
 
0
 
96
 
103
 
103
 
96
 
103
 
0
 
96
 
136
 
103
 
116
 
103
 
103
 
103
 
Max. Cumulative Volume
 
(mL)
 
 
12
2
 
22
5
 
22
5
 
32
1
 
42
4
 
5
2
7
 
62
3
 
7
2
6
 
727
 
82
2
 
9
5
8
 
1,06
1
 
1,1
7
7
 
1,28
0
 
1,38
3
 
1,48
6
 
* 
VRC
 
500:
 
S
creening evaluations
 
must
 
be no more
 
than
 
28
 
days
 
prior
 
to Day
 
0 
to
 
be
 
used for
 
eligibility
 
(pregnancy test
 
from
 
Day
 
0
 
must
 
be
 
used
 
for eligibility).
 
If
 
clinical
 
assessment
 
on
 
Day
 
0
 
suggests significant
 
changes
 
may 
have
 
occurred since
 
screening,
 
then
 
physical
 
examination
 
& 
laboratory studies
 
done on Day
 
0
 
are
 
used
 
for 
eligibility.
 
1
 
Day
 
0=day of
 
enrollment
 
and
 
first
 
vaccine
 
injection.
 
Day 
0
 
evaluations
 
prior
 
to
 
first
 
injection
 
are the baseline
 
for
 
assessing adverse
 
events
 
subsequently.
 
2
 
Screening visit
 
includes
 
physical exam with
 
vital
 
signs. At
 
other visits,
 
physical
 
examination
 
is
 
done
 
if
 
indicated. Otherwise 
only
 
blood
 
pressure (BP),
 
pulse,
 
temperature
, and respiration
 
are
 
required.
 
3 
Study
 
Product Administration
:
 
Group
s
 
2
A
-
2D
 
will
 
receive 
H1ssF_3928
 
60
 
mcg IM at Day 
0 
and
 
Week
 
16.
 
Complete
 
post
 
vaccination
 
evaluations
 
(BP, 
pulse,
 
temperature,
 
respiration
 
and
 
injection site
 
assessment)
 
at
 
30 minutes
 
or
 
longer
 
after
 
each 
injection
 
for 
Group 2A
-
2D
.
 
4
 
Negative
 
pregnancy
 
test
 
results
 
must
 
be
 
confirmed for
 
women of reproductive
 
potential
 
prior
 
to
 
each
 
study
 
injection
 
and prior to apheresis.
 
5 
HLA
 
type blood sample
 
is
 
collected
 
once at any
 
time
-
point
 
in
 
the
 
study
 
and
 
is
 
shown
 
as
 
a
 
Visit
 
0
5
 
evaluation
 
for
 
convenience;
 
however,
 
if
 
HLA
 
type is
 
already
 
available
 
in the
 
medical
 
record,
 
it
 
does
 
not
 
need
 
to
 
be
 
repeated.
 
HLA
 
type
 
may also
 
be obtained
 
from
 
a 
frozen sample.
 
6
 
Visit 0
3
: Two 
EDTA 
tubes
 
for
 
PBMC collected will be sent to
 
Building 40, while the rem
a
inder of the blood collected will be sent to 
VIP
.
 
7
 
If
 
optional 
Apheresis
 
occurs, ONLY draw 
16
 
mL in SST 
(DO NOT draw 120 ml in EDTA tubes)
.
 
 
8
For women of reproductive potential, pregnancy test must be negative within 72 hours prior to apheresis procedure.
 
Visit windows
:
 
Schedule Visits
 
02A 
-
 
0
7
 
with
 
respect
 
to Day 0; Schedule 
Visits
 
0
7
A
 
-
 
1
3
 
with respect
 
to Visit
 
0
7
. The following 
visit
 
windows apply:
 
Visits 02A and 0
7
A
 
(
+1 day). Visit
s
 
03 and 0
8
 
(±1 day). Visits
 
04
 
and 
09
 
(±2
 
days).
 
Visit
s
 
05 and 10 
(±2
 
days).
 
Visit
s
 
06 and 11 
(±
14
 
days). 
Visit 0
7
 
(±
14
 
day
s
)
. 
Visits
 
1
2
, 
1
3
 
and 14
 
(±14
 
days).
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
47
 
of 
54
 
APPENDIX
 
I
I
: 
ASSESSMENT OF RELATI
ONSHIP TO VACCINE AN
D GRADING 
SEVERITY 
OF 
ADVERSE EVENTS
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
48
 
of 
54
 
Assessment of Relationship of an Adverse Event to Study Vaccine
: 
 
 
The 
relationship between an AE and the vaccine will be assessed by the investigator on the basis 
of his or her clinical judgment and the definitions below.
 
•
 
Definitely Related
. 
The AE and administration of study agent are related in time, and 
a direct associati
on can be demonstrated.
 
•
 
Probably Related
. 
The AE and administration of study agent are reasonably related 
in time, and the AE is more likely explained by study agent than other causes. 
 
•
 
Possibly Related
. The AE and administration of study agent are 
reasonably related in 
time, but the AE can be explained equally well by causes other than study agent.
 
•
 
Not Related
. 
The 
AE
 
is clearly explained by another cause not related to the study 
product.
 
 
For purposes of preparing summary data reports in which 
AE
 
a
ttributions are simplified to 
“Related” or “Not Related”, in this protocol, the “Definitely, Probably and Possibly” attributions 
above will be mapped to the “Related” category, while the “Unlikely/Probably Not Related” and 
“Not Related” attributions above 
will be mapped to the “Not Related” category. The definitions 
that apply when these two attribution categories alone are used are as follows:
 
•
 
Related
 
–
 
There is a reasonable possibility that the AE may be related to the study 
product(s).
 
•
 
Not Related
 
–
 
Ther
e is not a reasonable possibility that the AE is related to the study 
product(s).
 
Grading the Severity of Adverse Events
:
 
The FDA Guidance for Industry (September 2007): “Toxicity Grading Scale for Healthy Adult 
and Adolescent Volunteers Enrolled in Preven
tive Vaccine Clinical Trials” is the basis for the 
severity grading of 
AE
s in this protocol. Several modifications were made to the table as follows:
 
•
 
“Emergency room visit” is not automatically considered a life
-
threatening event; these 
wor
ds have been rem
oved from any “G
rade 4
”
 
definition where they appear in the table 
copied from the guidance document.
 
•
 
L
aboratory value shown as a “graded” value in the table that is within the institutional 
normal range will not be severity graded or recorded as an 
AE
.
 
•
 
Sev
erity grading for hemoglobin decrease on the basis of the magnitude of decrease from 
bas
eline is not applicable at the G
rade 1 level; only absolute hem
oglobin will be used to 
define G
rade 1
.
 
•
 
Severity grading for Grade 4 local reaction to injectable product
 
(Erythema/Redness and 
Induration/Swelling) refer to necrosis or exfoliative dermatitis “requiring medical 
attention.”
 
•
 
Bruising or skin lesion associated with study injection will be assessed using the same 
severity grading as 
for 
erythema/redness.
 
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
49
 
of 
54
 
When not otherwise specified, the following guidance will be used to assign a severity grade:
 
•
 
Grade 1 (Mild)
: No 
effect on activities of daily living
 
•
 
Grade 2 (Moderate)
: Some interference with activity not requiring medical intervention
 
•
 
Grade 3 (Severe)
: Prevents daily activity and requires medical intervention 
 
•
 
Grade 4 (
Potentially 
Life
-
threatening)
: Hospitalization
; immediate medical 
intervention or therapy required to prevent death.
 
•
 
Grade 5 (Death)
: Death is assigned a Grade 5 severity. Only the single 
AE
 
that is 
assessed as the primary cause of death should be assigned “Grade 5” severity.
 
 
Toxicity Grading Scale f
or Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials
 
Modified from FDA Guidance
 
-
 
September 2007
 
 
A.
 
Tables for Clinical Abnormalities 
 
 
Local Reaction to 
 
Injectable Product 
 
Mild
 
 
(Grade 1) 
 
Moderate
 
(Grade 2) 
 
Severe 
 
(Grade 3) 
 
Potentially Life 
 
Threatening 
 
(Grade 4) 
 
Pain 
 
Does not 
interfere 
 
with activity 
 
Repeated use of 
non
-
narcotic 
pain reliever > 
24 hours or 
interferes with 
activity 
 
Any use of 
narcotic pain 
reliever or 
prevents daily 
 
activity 
 
Hospitalization 
 
Tenderness 
 
Mild discomfort 
to touch 
 
Discomfort with 
movement 
 
Significant 
 
discomfort at 
rest 
 
Hospitalization 
 
1
,2
Erythema/Redness  
 
2.5 
–
 
5 cm 
 
5.1 
–
 
10 cm 
 
> 10 cm 
 
Necrosis or 
 
exfoliative 
dermatitis 
requiring 
medical 
attention 
 
3
 
Induration/Swelling  
 
2.5 
–
 
5 cm and 
does not 
interfere 
 
with activity 
 
5.1 
–
 
10 cm or 
 
interferes with 
 
activity 
 
> 10 cm or 
 
prevents daily 
 
activity 
 
Necrosis 
requiring 
medical 
attention 
 
 
4
 
Vital Signs
 
Mild 
 
(Grade 1) 
 
Moderate
 
(Grade 2) 
 
Severe 
 
(Grade 3) 
 
Potentially Life 
 
Threatening 
 
(Grade 4) 
 
5
Fever (°C) 
 
           
 
(°F) 
 
38.0 
–
 
38.4 
 
100.4 
–
 
101.1 
 
38.5 
–
 
38.9 
 
101.2 
–
 
102.0 
 
39.0 
–
 
40 
 
102.1 
–
 
104 
 
> 40 
 
> 104 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
50
 
of 
54
 
4
 
Vital Signs
 
Mild 
 
(Grade 1) 
 
Moderate
 
(Grade 2) 
 
Severe 
 
(Grade 3) 
 
Potentially Life 
 
Threatening 
 
(Grade 4) 
 
Tachycardia 
-
 
beats 
per 
 
minute 
 
 
101 
–
 
115 
 
116 
–
 
130 
 
> 130 
 
Hospitalization 
for arrhythmia 
 
6
Bradycardia 
-
 
beats 
per Minute
 
50 
–
 
54 
 
45 
–
 
49 
 
< 45 
 
Hospitalization 
for arrhythmia 
 
Hypertension 
(systolic) 
-
 
mm Hg 
 
141 
–
 
150 
 
151 
–
 
155 
 
> 155 
 
Hospitalization 
for malignant 
 
hypertension 
 
Hypertension 
(diastolic) 
-
 
mm Hg 
 
91 
–
 
95 
 
96 
–
 
100 
 
> 100 
 
Hospitalization 
for malignant 
 
hypertension 
 
Hypotension 
(systolic) 
–
 
mm Hg 
 
85 
–
 
89 
 
80 
–
 
84 
 
< 80 
 
Hospitalization 
for hypotensive 
shock 
 
Respiratory Rate 
–
 
breaths per minute 
 
17 
–
 
20 
 
21 
–
 
25 
 
> 25 
 
Intubation 
 
 
1.
 
In addition to grading the measured local reaction at the greatest single diameter, the measurement 
should be recorded as a continuous vari
able. 
 
2.
 
Bruising or skin lesion associated with study injection will be assessed using the same severity 
grading as 
for 
erythema/redness.
 
3.
 
Induration/Swelling should be evaluated and graded using the functional scale as well as the actual 
measurement.
 
4.
 
Subject should be at rest for all vital sign measurements. 
 
5.
 
Oral temperature; no recent hot or cold beverages or smoking. 
 
6.
 
When resting heart rate is between 60 
–
 
100 beats per minute. Use clinical judgment when 
characterizing 
 
 
Bradycardia among some heal
thy subject populations, for example, conditioned athletes.
 
 
Systemic 
(General) 
 
Mild 
 
(Grade 1) 
 
Moderate
 
(Grade 2) 
 
Severe 
 
(Grade 3) 
 
Potentially Life 
 
Threatening 
 
(Grade 4) 
 
Nausea/vomiting 
 
No interference 
 
with activity or 1 
–
 
2
 
 
episodes/24 hours 
 
Some 
interference 
 
with activity or > 
2 
 
episodes/24 
hours 
 
Prevents daily 
 
activity, requires 
 
outpatient IV 
 
hydration 
 
Hospitalization 
for hypotensive 
shock 
 
Systemic 
(General) 
 
Mild 
 
(Grade 1) 
 
Moderate
 
(Grade 2) 
 
Severe 
 
(Grade 3) 
 
Potentially Life 
 
Threatening 
 
(Grade 4) 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
51
 
of 
54
 
Diarrhea 
 
2 
–
 
3 loose stools 
or
 
< 400 gms/24 
hours
 
4 
–
 
5 stools or 
 
400 
–
 
800 
gms/24 
 
hours 
 
6 or more watery 
 
stools or 
 
> 800gms/24 
hours or requires 
 
outpatient IV 
 
hydration 
 
Hospitalization 
 
Headache 
 
No interference 
with
 
activity 
 
Repeated use of 
non
-
narcotic 
pain 
 
reliever > 24 
hours or
 
some 
interference 
 
with activity 
 
Significant; any 
 
use of narcotic 
 
pain reliever or 
 
prevents daily 
 
activity 
 
Hospitalization 
 
Fatigue 
 
No 
interference 
with
 
activity 
 
Some 
interference 
 
with activity 
 
Significant; 
 
prevents daily 
 
activity 
 
Hospitalization 
 
Myalgia 
 
No interference 
with
 
activity 
 
Some 
interference 
 
with activity 
 
Significant; 
 
prevents daily 
 
activity 
 
Hospitalization 
 
Illn
ess or clinical 
adverse 
 
event (as defined 
 
according to 
applicable 
 
regulations) 
 
No interference 
with
 
activity 
 
Some
 
interference 
 
with activity not 
 
requiring 
medical 
 
intervention 
 
Prevents daily 
 
activity and 
 
requires medical 
 
intervention 
 
Hospitalization 
 
 
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
52
 
of 
54
 
B. Tables for Laboratory Abnormalities 
 
 
The laboratory values provided in the tables below serve as guidelines and are dependent upon 
the institutional normal parameters. Institutional normal reference ranges should be p
rovided to 
demonstrate that they are appropriate.
 
 
Serum * 
 
Mild 
 
(Grade 1) 
 
Moderate 
 
(Grade 2) 
 
Severe 
 
(Grade 3) 
 
Potentially Life 
 
Threatening 
 
(Grade 4) 
**
 
Sodium 
–
 
Hyponatremia 
mEq/L 
 
132 
–
 
134 
 
130 
–
 
131 
 
125 
–
 
129 
 
< 125 
 
Sodium 
–
 
Hypernatremia 
mEq/L 
 
144 
–
 
145 
 
146 
–
 
147 
 
148 
–
 
150 
 
> 150 
 
Potassium 
–
 
Hyperkalemia 
mEq/L 
 
5.1 
–
 
5.2 
 
5.3 
–
 
5.4 
 
5.5 
–
 
5.6 
 
> 5.6 
 
Potassium 
–
 
Hypokalemia 
mEq/L 
 
3.5 
–
 
3.6 
 
3.3 
–
 
3.4 
 
3.1 
–
 
3.2 
 
< 3.1 
 
Glucose 
–
 
Hypoglycemia 
mg/dL 
 
65 
–
 
69 
 
55 
–
 
64 
 
45 
–
 
54 
 
< 45 
 
Glucose 
–
 
Hyperglycemia 
 
Fasting 
–
 
mg/dL 
 
Random 
–
 
mg/dL 
 
 
100 
–
 
110 
 
110 
–
 
125 
 
 
111 
–
 
125 
 
126 
–
 
200 
 
 
>125 
 
>200 
 
Insulin 
requirements or 
hyperosmolar 
coma 
 
Blood Urea Nitrogen 
 
BUN mg/dL 
 
23 
–
 
26 
 
27 
–
 
31 
 
> 31 
 
Requires dialysis 
 
Creatinine 
–
 
mg/dL 
 
1.5 
–
 
1.7 
 
1.8 
–
 
2.0 
 
2.1 
–
 
2.5 
 
> 2.5 or requires 
dialysis 
 
Calcium 
–
 
hypocalcemia 
mg/dL 
 
8.0 
–
 
8.4 
 
7.5 
–
 
7.9 
 
7.0 
–
 
7.4 
 
< 7.0 
 
Calcium 
–
 
hypercalcemia 
mg/dL 
 
10.5 
–
 
11.0 
 
11.1 
–
 
11.5 
 
11.6 
–
 
12.0 
 
> 12.0 
 
Magnesium 
–
 
hypomagnesemia mg/dL 
 
1.3 
–
 
1.5 
 
1.1 
–
 
1.2 
 
0.9 
–
 
1.0 
 
< 0.9 
 
Phosphorous 
–
 
hypophosphatemia mg/dL 
 
2.3 
–
 
2.5 
 
2.0 
–
 
2.2 
 
1.6 
–
 
1.9 
 
< 1.6 
 
CPK 
–
 
mg/dL 
 
1.25
 
–
 
1.5
 
x
 
ULN**
*
 
 
>1.5 
–
 
3.0 x 
ULN 
 
>3.0 
–
10 x 
ULN 
 
> 10 x ULN 
 
Albumin 
–
 
Hypoalbuminemia g/dL 
 
2.8 
–
 
3.1 
 
2.5 
–
 
2.7 
 
< 2.5 
 
--
 
 
Total Protein 
–
 
Hypoproteinemia g/dL 
 
5.5 
–
 
6.0 
 
5.0 
–
 
5.4 
 
< 5.0 
 
--
 
 
Alkaline phosphate 
–
 
 
increase by factor 
 
1.1 
–
 
2.0 x 
ULN 
 
2.
1
 
–
 
3.0 x 
ULN 
 
>
 
3.0 
–
 
10 x 
ULN 
 
> 10 x ULN 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
53
 
of 
54
 
Serum * 
 
Mild 
 
(Grade 1) 
 
Moderate 
 
(Grade 2) 
 
Severe 
 
(Grade 3) 
 
Potentially Life 
 
Threatening 
 
(Grade 4) 
**
 
Liver Function Tests 
–
ALT, AST increase by 
factor 
 
1.1 
–
 
2.5 x 
ULN 
 
>
 
2.6
 
–
 
5.0 x 
ULN 
 
>
 
5.
1
 
–
 
10 x 
ULN 
 
> 10 x ULN 
 
Bilirubin 
–
 
when 
accompanied by any 
increase in Liver Function 
Test 
 
increase by factor 
 
1.1 
–
 
1.25 x 
U
LN 
 
>
 
1.26
 
–
 
1.5 x 
ULN 
 
>
 
1.5
1
 
–
 
1.
75 x ULN 
 
> 1.75 x ULN 
 
Bilirubin 
–
 
when Liver 
Function Test is normal; 
increase by factor 
 
1.1 
–
 
1.5 x 
ULN 
 
1.
6
 
–
 
2.0 x 
ULN 
 
2.0 
–
 
3.0 x 
ULN 
 
> 3.0 x ULN 
 
Cholesterol 
 
201 
–
 
210 
 
211 
–
 
225 
 
> 226 
 
---
 
 
Pancreatic enzymes 
–
 
amylase, lipase 
 
1.1 
–
 
1.5 x 
ULN 
 
1.
6
 
–
 
2.0 x 
ULN 
 
2.
1
 
–
 
5.0 x 
ULN 
 
> 5.0 x ULN 
 
* The laboratory values provided in the tables serve as guidelines and are dependent upon 
institutional normal parameters. Institutional normal reference
 
ranges should be provided to 
demonstrate that they are appropriate.
 
** The clinical signs or symptoms associated with laboratory abnormalities might result in 
characterization of the laboratory abnormalities as Potentially Life Threatening (Grade 4). For 
example, a low sodium value that falls within a Grade 3 parameter (125
-
129 mE/L) should be 
recorded as a Grade 4 hyponatremia event if the subject had a new seizure associated with the 
low sodium value.
 
***ULN” is the upper limit of the normal range.
 
 
 
 
PRODUCT: 
VRC
-
FLUNPF099
-
00
-
VP
 
PROTOCOL: VRC 3
2
1, VERSION 
3.
0
 
PROTOCOL DATE: APRIL
 
20
, 2020
 
Page 
54
 
of 
54
 
He
matology * 
 
Mild 
 
(Grade 1) 
 
Moderate 
 
(Grade 2) 
 
Severe 
 
(Grade 3) 
 
Potentially Life 
 
Threatening 
(Grade 4) 
 
Hemoglobin (Female) 
-
 
gm/dL 
 
11.0 
–
 
12.0 
 
9.5 
–
 
10.9 
 
8.0 
–
 
9.4 
 
< 8.0 
 
Hemoglobin (Female) 
 
decrease from baseline 
value 
-
 
gm/dL 
 
not 
applicable
 
1.6 
–
 
2.0 
 
2.1 
–
 
5.0 
 
> 5.0 
 
Hemoglobin (Male) 
-
 
gm/dL 
 
12.5 
–
 
13.5 
 
10.5 
–
 
12.4 
 
8.5 
–
 
10.4 
 
< 8.5 
 
Hemoglobin (Male) 
 
decrease from baseline 
value 
–
 
gm/dL 
 
not 
applicable 
 
1.6 
–
 
2.0 
 
2.1 
–
 
5.0 
 
> 5.0 
 
WBC Increase 
-
 
cell/mm
3
 
10,800 
–
 
15,000 
 
15,001 
–
 
20,000 
 
20,001 
–
 
25, 
000 
 
> 25,000 
 
WBC Decrease 
-
 
cell/mm
3
 
2,500 
–
 
3,500 
 
1,500 
–
 
2,499 
 
1,000 
–
 
1,499 
 
< 1,000 
 
Lymphocytes Decrease 
-
 
cell/mm
3
 
750 
–
 
1,000 
 
500 
–
 
749 
 
250 
–
 
499 
 
< 250 
 
Neutrophils Decrease 
-
 
cell/mm
3
 
1,500 
–
 
2,000 
 
1,000 
–
 
1,499 
 
500 
–
 
999 
 
< 500 
 
Eosinophils 
-
 
cell/mm
3
 
650 
–
 
1500 
 
1501 
-
 
5000 
 
> 5000 
 
Hypereosinophilic 
 
Platelets Decreased 
-
 
cell/mm
3
 
125,000 
–
 
140,000 
 
100,000 
–
 
124,000 
 
25,000 
–
 
99,000 
 
< 25,000 
 
PT 
–
 
increase by factor 
 
(prothrombin time) 
 
1.10 x 
ULN** 
 
>
 
1.1
1
 
–
 
1.2
0
 
x 
ULN 
 
1.2
1
 
–
 
1.25 
x ULN 
 
> 1.25 ULN 
 
PTT 
–
 
increase by factor 
(partial thromboplastin 
time) 
 
1.10 
–
 
1.20 
x ULN 
 
1.2
1
 
–
 
1.4 x 
ULN 
 
1.4 
–
 
1.5 x 
ULN 
 
> 1.5 x ULN 
 
Fibrinogen increase 
-
 
mg/dL 
 
400 
–
 
500 
 
501 
–
 
600 
 
> 600 
 
--
 
 
Fibrinogen decrease 
-
 
mg/dL 
 
150 
–
 
200 
 
125 
–
 
149 
 
100 
–
 
124 
 
< 100 or 
a
ssociated with 
gross bleeding 
 
or disseminated 
intravascular 
coagulation (DIC) 
 
* The laboratory values provided in the tables serve as guidelines and are dependent upon 
institutional normal parameters. Institutional normal reference 
ranges should be provided to 
demonstrate that they are appropriate.
 
**ULN” is the upper limit of the normal range.
 
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
1
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
PRINCIPAL INVESTIGATOR:  Alicia Widge, MD, MS
STUDY TITLE: VRC 321: A Phase I Open-Label Clinical Trial to Evaluate Dose, Safety, 
Tolerability, and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine, 
VRCFLUNPF099-00-VP, in Healthy Adults
STUDY SITE: NIAID/VRC
Cohort: 
Healthy volunteer
Consent Version:  
3.0, April 20, 2020
WHO DO YOU CONTACT ABOUT THIS STUDY? 
Principal Investigator: Alicia Widge, MD, MS; 301-761-7968; 
alicia.widge@nih.gov 
Study Coordinator: Floreliz Mendoza, RN; 301-451-8715; 
mendozaf@mail.nih.gov
This consent form describes a research study and is designed to help you decide if you would like 
to be a part of the research study.  
You are being asked to take part in a research study at the National Institutes of Health (NIH). 
Members of the study team will talk with you about the information described in this document. 
Some people have personal, religious, or ethical beliefs that may limit the kinds of medical or 
research treatments they would want to receive (such as blood transfusions). Take the time needed 
to ask any questions and discuss this study with NIH staff, and with your family, friends, and 
personal health care providers. Taking part in research at the NIH is your choice.
IT IS YOUR CHOICE TO TAKE PART IN THE STUDY
You may choose not to take part in this study for any reason. If you join this study, you may change 
your mind and stop participating in the study at any time and for any reason. In either case, you 
will not lose any benefits to which you are otherwise entitled. However, to be seen at the NIH, you 
must be taking part in a study or are being considered for a study. If you do choose to leave the 
study, please inform your study team to ensure a safe withdrawal from the research.  
WHY IS THIS STUDY BEING DONE?
This is the first study in people of this experimental vaccine for prevention of H1 influenza (flu). 
“Experimental” means that the study vaccine has not been approved by the Food and Drug 
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
2
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Administration (FDA). The FDA allows this vaccine to be used for research purposes only. We do 
not know if this vaccine works. The main purpose of this study is to see if the experimental vaccine 
is safe and if there are any side effects. We also want to study immune responses to this vaccine.
STUDY VACCINE
Vaccines are given to teach the body to prevent or fight an infection. In this study, we are testing 
one experimental vaccine that was developed by the Vaccine Research Center (VRC) at the NIH: 
H1 Stabilized Stem Ferritin vaccine, VRC-FLUNPF099-00-VP. In this consent form, the study 
vaccine will be called the “H1 Ferritin vaccine.”
This vaccine is intended to help the body to make an immune response to H1 flu, which is a strain 
of flu that infects humans.
Most vaccines are made of proteins that are injected into a muscle. Proteins are natural substances 
that the body uses as building blocks. This vaccine is made in the laboratory with two proteins: 
one protein from the H1 flu virus and one protein from a type of bacteria called 
Helicobacter pylori 
(
H. pylori
). These two proteins have been modified in the laboratory. When combined, they make 
a particle that looks like the outside of the H1 flu virus. The body’s immune system may respond 
to this particle. There is no virus or bacteria in the vaccine, so you cannot get an H1 flu infection 
or
 H. pylori
 infection from this vaccine.
We do not know if the H1 Ferritin vaccine will protect you from flu. 
ELIGIBILITY
You are eligible to take part in this study because you have completed the screening process and 
are:

18-70 years old

In general good health without significant medical problems as determined at screening

Willing to get the experimental vaccine

Willing to donate blood samples for future research

Willing to use birth control from at least 21 days prior to enrollment through the end of 
the study, if female and able to become pregnant

Must have received a licensed influenza (flu) vaccine at least once since January 1, 2014.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
3
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
STUDY PLAN
About 53 people will take part in this study at the NIH Clinical Center in Bethesda, MD. 
If you are enrolled in Group 1, you will get one vaccination and remain in the study for about one 
year. 
If you are enrolled in Groups 2A, Group 2B, Group 2C, or Group 2D you will get two vaccinations 
and remain in the study for about one year and three months.
You will get the experimental vaccine by injections (shots) in the upper arm muscle. This is called 
an intramuscular “IM” injection. We will use a needle and syringe to give you the H1 Ferritin 
vaccine. We will check you for any side effects from the vaccine. 
We will tell you if we learn anything new during this study that might cause you to change your 
mind about staying in the study. At the end of the study, we will tell you when study results may 
be available and how to learn about them.
There will be two different doses of vaccine given in this study, a lower dose (20 mcg) and a higher 
dose (60 mcg).
Group 1 will get the lower dose of the H1 Ferritin vaccine one time on the day of enrollment. If 
there are no safety concerns at this dose after 2 weeks of follow-up, we will start enrolling people 
to get the higher dose.
Groups 2A, 2B, 2C, 2D will get the higher dose of the H1 Ferritin vaccine on the day of the 
enrollment and about 4 months later (week 16). Groups are based on age. This is done so that 
researchers may compare the immune response of people of different ages. 
The table below shows the study plan: 
Group
Age 
Subjects
Day 0
Week 16  
1
18-40
5
20 mcg
2A
18-40
12
60 mcg
60 mcg
2B
41-49
12
60 mcg
60 mcg
2C
50-59
12
60 mcg
60 mcg
2D
60-70
12
60 mcg
60 mcg
Total
53
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
4
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
STUDY PROCEDURES
If you agree to take part in the study and are enrolled in:
Group 1: you will have 1 vaccination visit, 1 phone follow-up, and 9 follow-up clinic visits. 
Groups 2A, 2B, 2C, 2D: you will have 2 vaccination visits, a phone follow-up after each 
vaccination, and 11 follow-up clinic visits.
If you are a woman who can get pregnant, we will do a pregnancy test before each injection. The 
test must show that you are not pregnant before you can get the injection.
Each vaccination visit will take about 4 to 6 hours. Most follow-up clinic visits will take about 1 
to 2 hours; the optional apheresis visit will take 2 to 4 hours.
If you are enrolled in Group 1 you will need to stay in the clinic for at least 1 hour after your 
vaccination. If you are enrolled in Group 2A, 2B, 2C, or 2D, you will need to stay in the clinic for 
at least 30 minutes after each vaccination. 
After each vaccination, the clinic staff will call to check on you. Also, after each vaccination, you 
will need to complete a diary card for 7 days. The purpose of the diary card is to record any 
symptoms that you may have for data analysis and not because of any risk of getting the flu from 
this vaccine. We will give you a thermometer to record your temperature even if you feel well. We 
will also give you a ruler to measure any skin changes at the injection site.  You will get a password 
to a secure website where you can enter this data online. If you do not have access to the internet, 
you can use a paper diary card instead.
If you have any symptoms or feel unwell, you should tell a clinic nurse or doctor as soon as 
possible. You can reach the staff by phone 24 hours a day. If you have symptoms, you may be 
asked to come to the clinic for a checkup. It is very important that you follow the instructions from 
the clinic staff. 
At each visit, we will check you for any health changes or problems. We will ask you how you are 
feeling and if you have taken any new medications. We will draw your blood at each visit, taking 
about 6 to 14 tubes of blood per visit. We will tell you right away if any of your test results show 
a health problem. Some blood samples will be used for research only so that we can study your 
immune response to the vaccine. Results of these research tests are not used to check your health 
and will not be given to you.
Mucosal Swab
: It is very important to report symptoms including fever of 100
0
 F or higher, runny 
nose, sore throat, headache, feeling more tired than usual or muscle aches. This group of symptoms 
may be the flu or a flu-like illness. You will need to come to the clinic so that we can do a nose 
and throat swab. We will use a thin disposable swab to collect this sample. Each swab is new and 
sterile and is safe for use in sensitive parts of the body.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
5
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Apheresis
: For subjects enrolled in Group 2A, Group 2B, Group 2C, and Group 2D, after your 
last study injection, we would like to collect your blood by a method called “apheresis.” This 
procedure is optional and choosing not to take part in it will not affect your study participation.
To be eligible for apheresis:

You must not have an unstable heart as indicated by your medical history and test results

You must not have blood pressure greater than 180/100

You must not have a known blood clotting disorder

You must not be pregnant or breast feeding

You must not have a condition that the attending physician or the apheresis clinic staff 
considers a reason to not do an apheresis procedure.
Before apheresis, we will check your weight, pulse and blood pressure. We will ask questions 
about your general health and medical history.  If you are a woman who can get pregnant, we will 
do a pregnancy test before the apheresis procedure. The test must show that you are not pregnant.
During the procedure, you will lie on a recliner, couch, or hospital bed. The procedure requires 
that a needle be placed into a vein in both arms using a sterile method. The kits used to collect 
apheresis samples are sterile, single-use, disposable sets that are not in contact with any person’s 
bodily fluids other than yours. No blood products are given to you during these procedures. The 
apheresis is done at the NIH Clinical Center, and a physician from the NIH Department of 
Transfusion Medicine will be available in or near the apheresis area at all times.
In the apheresis procedure, blood is removed through a needle in the vein of one arm, spun in a 
machine that separates the desired blood components (white blood cells) and then the rest of your 
blood is returned to you through a needle in the other arm. Citrate, a medication to prevent blood 
from clotting, is added to the blood while in the machine to prevent it from clotting.
The purpose of this procedure is to allow us to get and study a larger number of white blood cells 
that cannot be collected by simple blood drawing. The number of white blood cells collected is a 
small fraction of the total amount in your body. The body quickly replaces cells that have been 
removed. The Blood Bank of the NIH Clinical Center and other blood banks use similar procedures 
every day to collect blood samples from donors and as a form of therapy for some diseases. 
However, we will not use your samples for transfusion or therapy. The procedure will take 
approximately 1-3 hours.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
6
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
MONITORING OF THE STUDY
This study will be monitored by a group of physicians and scientists at NIH. This group will review 
the study information and will pay close attention to any reactions. If there are serious side effects, 
study injections may be delayed or canceled.
GENETIC TESTING
Some of the blood drawn from you during this study will be used for genetic tests. Some genetic 
tests are done in research studies to see if genetic differences in people cause different types of 
immune responses. Your blood sample used in these genetic tests will not have your name on it 
and the results will not be in your medical record except for Human Leukocyte Antigen (HLA) 
typing results. These tests are not used to check your health and we will not tell you the results. 
A special genetic test, called HLA typing, is done by the NIH Clinical Center medical laboratory. 
These results will be in your medical record, but they will not be used to check your health. Any 
genetic testing, including HLA testing, is for research purposes only. Any genetic information 
collected or learned about you will be kept confidential. Medical records, including HLA test 
results are kept securely. We will not give any genetic information that is in your medical record 
to anyone without your permission.
STORED SAMPLES
We will collect blood samples from you during the study. We will keep these samples for future 
research indefinitely to learn more about flu virus, vaccines, the immune system, and other 
research questions. Results from research with your samples will not be in your medical record or 
reported to you.
Labeling of Stored Samples
: Your stored samples will be labeled by a special code or number 
and not your personal information. Only the study team can link this code to you. Any identifying 
information about you (like name or date of birth) will be kept as confidential as allowable by law.
Risks of Stored Samples
: There is a risk of unplanned release of information from your medical 
record. The chance that this information will be given to an unauthorized person without your 
permission is very small. Possible problems with the unplanned release of information include 
discrimination when applying for insurance or employment. Similar problems may occur if you 
give information about yourself or agree to have your medical record released.
Future studies: 
In the future, other investigators at NIH or outside of NIH may wish to study your 
stored samples. When your stored samples are shared, they will be marked with a code. Your 
samples will not have any identifying information on them. Some information about you, like your 
gender, age, health history, or ethnicity may be shared with other researchers. Any future research 
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
7
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
studies using your samples will be conducted in a way that protects the rights and privacy of study 
participants.
Your stored samples will only be used for research and will not be sold. The research done with 
your materials may be used to develop new products in the future, but you will not receive payment 
for such products.
Making your Choice: 
You cannot take part in this study if you do not want us to collect or store 
your blood samples. If you agree to take part in this study, you must also agree to let us keep any 
of your samples and data for future research.
If you decide not to take part in this study, you may still take part in other studies at NIH.
POSSIBLE STUDY RISKS
Possible 
risks of injections: 
Temporary stinging, pain, redness, soreness, itchiness, swelling, or 
bruising. 
Possible 
risks of any vaccine: 
Fever, chills, rash, aches and pains, nausea, headache, dizziness, 
and feeling tired and/or unwell. These types of reactions are usually greatest within the first 24 
hours after vaccination and typically last 1 to 3 days. Over-the-counter medicine, like 
acetaminophen (Tylenol) or ibuprofen, may be used to help these symptoms. 
Very rarely, a serious allergic reaction with symptoms like hives, trouble breathing, or sudden 
weakness may occur shortly after any vaccination. This is called “anaphylaxis” and may be life-
threatening. While you are waiting in the clinic after the vaccination, we will monitor you for 
anaphylaxis. Treatment for anaphylaxis will be given right away if it occurs.
Possible
 risks of the H1 Ferritin vaccine
: The H1 Ferritin vaccine has not been given to people 
before. It may have unknown risks. It has been tested in mice and rabbits. The vaccine did not 
cause any unusual side effects and met the safety criteria to be tested in humans.
Possible 
risks of blood drawing:
 Pain, bleeding, bruising, feeling lightheaded, and fainting. 
Rarely, infection may occur at the site where the blood is taken.
Possible 
risks of mucosal sample collection: 
Samples collected by rubbing swabs over mucosal 
surfaces in the mouth or in the nose can cause brief discomfort, or a little bleeding.
Possible
 risks of apheresis
: Apheresis is generally safe and side effects are rare. Pain, bruising or 
discomfort at the needle placement site may occur. Sometimes apheresis causes a tingling 
sensation around the lips, nose and mouth, coolness all over and slight nausea. This can usually be 
relieved by slowing or temporarily stopping the apheresis or taking an antacid with calcium pill, 
like Tums
®
. Other possible side effects are anxiety, vomiting and lightheadedness. Temporary 
lowering of the blood pressure may develop. There is the rare possibility of infection, fainting or 
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
8
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
seizure. Very rarely a nerve problem at the needle placement site may occur. Also, very rarely, a 
machine malfunction may occur and result in the loss of about one unit (one pint) of blood.
There are theoretical risks from re-infusion of the blood after processing by the machine such as 
infection or an adverse reaction to the blood components. However, this has not been seen in many 
thousands of volunteers who have undergone this or similar procedures to date. There may be other 
risks of apheresis that are unknown at this time.
Unknown
 safety risks
: There may be side effects from the study vaccines - even serious or life-
threatening ones- that we do not yet know about. Please tell the study staff about any side effect 
you think you are having. This is important for your safety.
Possible
 risks of genetic testing
: Unplanned release of information that could be used by insurers 
or employers to discriminate against you or your family; discovering a gene that suggests risk of 
disease for you or your family; discovering unknown family relationships.
Possible
 risks of data sharing:  
Information in the shared databases could be linked back to you 
and used to discriminate against you or your family.  State and federal laws provide some 
protections against genetic and pre-existing conditions discrimination.
Possible
 risks during pregnancy
: We do not know how the experimental vaccines may affect a 
fetus or nursing infant. Therefore, women who can become pregnant must have a negative 
pregnancy test before each injection and agree to use effective birth control beginning at least 21 
days before the first injection until the end of the study. We will discuss effective methods of birth 
control with you. 
You must tell the clinic staff right away if you become pregnant or think that you might be pregnant 
during the study. If you are pregnant, you will not get any more vaccinations. You will be asked 
to continue with follow-up visits so that we can check your health. We will ask you the outcome 
of the pregnancy.
Possible
 other risks
: We do not know if the study vaccine will change how your body responds 
to flu virus infections in the future.
You may not donate blood at a blood bank while taking part in this study. You may not donate 
blood for one year after the last experimental vaccine injection.
POSSIBLE BENEFITS
This study is not designed to benefit you. We do not know if the vaccines will work. The study is 
not designed to protect you from flu. You and others may benefit in the future from the information 
that will be learned from the study. The study visits are used to check your health for research 
purposes, not to provide health care. However, we will tell you right away if any of your test results 
show a possible health problem.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
9
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
REASONS FOR STOPPING STUDY INJECTIONS
You may not get all of your planned study vaccinations. Reasons for this may include:

You don’t keep appointments or follow procedures

You get a serious illness that needs ongoing medical care.

You have a serious side effect, thought to be due to the study vaccine.

You become pregnant.

You need to get treatment with a medication that affects your immune system (such as 
a steroid like prednisone).

The study is stopped by regulatory agencies, the study sponsor or study investigators. 
If this happens, we will tell you why.
If you agree to take part in this study, it is important for you to keep all of your appointments. Your 
participation in this study is completely voluntary. You can choose to stop taking part in the study 
at any time. There is no penalty or loss of benefits if you choose to leave the study.
If you are not able to get the second injection (for Groups 2A, Group 2B, Group 2C, and Group 
2D), we will adjust your schedule but will ask that you still have study visits. It is important that 
we continue to check your health even if you do not get a second injection.
ALTERNATIVES
This study is not designed to treat or prevent any disease. You may choose to not take part in this 
study. You may be eligible for other studies. 
CONFLICT OF INTEREST
The NIH research staff is checked yearly for conflicts of interest. You may ask the research team 
for more information. This study may have investigators who are not NIH employees. Non-NIH 
investigators are expected to follow the principles of the Protocol Review Guide but are not 
required to report their personal financial holdings to the NIH. 
The NIH, including some members of the VRC scientific staff, developed the investigational 
vaccines being used in this research study. The results of this study could play a role in whether 
the FDA will approve the vaccine for sale at some time in the future. If approved, the future sale 
of the vaccine could lead to payments to NIH and some NIH scientists. By U.S. law, government 
scientists are required to receive such payments for their inventions. You will not get any money 
from the development or sale of the product. 
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
10
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
COMPENSATION, REIMBURSEMENT, AND PAYMENT
Will you receive compensation for participation in the study?
Some NIH Clinical Center studies offer compensation for participation in research. The amount 
of compensation, if any, is guided by NIH policies and guidelines.
You will be compensated for your time and inconvenience by the NIH Clinical Research Volunteer 
Program. It is possible that you may have some expenses that are not covered by the compensation 
provided.
The compensation is $275 for each vaccination visit. You will get $25 total for the timely 
completion of all 7 days of an electronic diary. You will get $175 for each scheduled follow-up 
visit that includes a research blood draw. You will get $75 for all other clinic visits that do not 
include research blood draws or mucosal sample collection. You will get $250 for apheresis 
procedure. You will get an additional $50 for any visit that also includes a nose and throat swab.
If you are enrolled in Group 1, the total compensation for completion of all study visits is about 
$1,875.
If you are enrolled in Groups 2A, 2B, 2C, or 2D, the total compensation for completion of all study 
visits is about $2,525 without apheresis and about $2,600 with apheresis.
If you are unable to finish the study, you will receive compensation for the visits and for the parts 
you completed.  
With few exceptions, study compensation is considered taxable income that is reportable to the 
Internal Revenue Service (IRS). A “Form 1099-Other Income” will be sent to you if your total 
payments for research participation are $600 or more in a calendar year. If you have unpaid debt 
to the federal government, please be aware that some or all of your compensation may be 
automatically reduced to repay that debt on your behalf.
Will you receive reimbursement or direct payment by NIH as part of your participation?
Some NIH Clinical Center studies offer reimbursement or payment for travel, lodging or meals 
while participating in the research. The amount, if any, is guided by NIH policies and guidelines.
This study does not offer reimbursement for, or payment of, travel, lodging or meals. 
Will taking part in this research study cost you anything? 
NIH does not bill health insurance companies or participants for any research or related clinical 
care that you receive at the NIH Clinical Center. 
There are no costs to you for taking part in this study. We will not charge you or your insurance 
carrier for any health evaluations or services. You or your health insurance will have to pay for all 
costs for medical care that you get outside this study. It is possible that you may have some costs 
that are not covered by the study compensation we give you.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
11
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
CLINICAL TRIAL REGISTRATION AND RESULTS REPORTING 
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required 
by U.S. Law. This Web site will not include information that can identify you. At most, the Web 
site will include a summary of the results. You can search this Web site at any time.
HUMAN DATA SHARING
To advance science, it is helpful for researchers to share information they get from studying 
humans by putting it into shared scientific databases. Researchers can then study the information 
combined from many studies to learn even more about health and diseases.
If you agree to take part in this study, some of your data will be put into one or more scientific 
databases. We will remove identifying information like your name, address, and birth date. The 
data may then be used for future research and shared broadly for research purposes.
Only researchers who are approved to access the database may be able to see and use your 
information. You will not get any direct benefits from future research that uses your data and 
information.
You may stop participating in this study at any time and withdraw permission for your individual 
data, specimens, and health information to be used for additional or future research. You may ask 
to have your research data destroyed. However, it may not be possible to withdraw or delete data 
once they have been shared with other researchers.
Will your medical information be kept private? 
We will do our best to make sure that the personal information in your medical record will be kept 
private.  However, we cannot guarantee total privacy.  Organizations that may look at and/or copy 
your medical records for research, quality assurance, and data analysis include:

The NIH and other government agencies, like the Food and Drug Administration (FDA), 
which are involved in keeping research safe for people.

National Institutes of Health Intramural Institutional Review Board

The study Sponsor VRC or their agent(s) 
When results of an NIH research study are reported in medical journals or at scientific meetings, 
the people who take part are not named and identified.  In most cases, the NIH will not release any 
information about your research involvement without your written permission.  However, if you 
sign a release of information form, for example, for an insurance company, the NIH will give the 
insurance company information from your medical record.  This information might affect (either 
favorably or unfavorably) the willingness of the insurance company to sell you insurance.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
12
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
If we share your specimens or data with other researchers, in most circumstances we will remove 
your identifiers before sharing your specimens or data. You should be aware that there is a slight 
possibility that someone could figure out the information is about you. 
Further, the information collected for this study is protected by NIH under a Certificate of 
Confidentiality and the Privacy Act. 
Certificate of Confidentiality
To help us protect your privacy, the NIH Intramural Program has received a Certificate of 
Confidentiality (Certificate). With this certificate, researchers may not release or use data or 
information about you except in certain circumstances.  
NIH researchers must not share information that may identify you in any federal, state, or local 
civil, criminal, administrative, legislative, or other proceedings, for example, if requested by a 
court.  
The Certificate does not protect your information when it:  
1. is disclosed to people connected with the research, for example, information may be used 
for auditing or program evaluation internally by the NIH; or 
2. is required to be disclosed by Federal, State, or local laws, for example, when information 
must be disclosed to meet the legal requirements of the federal Food and Drug 
Administration (FDA); 
3. is for other research;
4. is disclosed with your consent. 
The Certificate does not prevent you from voluntarily releasing information about yourself or your 
involvement in this research. 
The Certificate will not be used to prevent disclosure to state or local authorities of harm to self or 
others including, for example, child abuse and neglect, and by signing below you consent to those 
disclosures. Other permissions for release may be made by signing NIH forms, such as the Notice 
and Acknowledgement of Information Practices consent.
Privacy Act
The Federal Privacy Act generally protects the confidentiality of your NIH medical records we 
collect under the authority of the Public Health Service Act.  In some cases, the Privacy Act 
protections differ from the Certificate of Confidentiality.  For example, sometimes the Privacy Act 
allows release of information from your medical record without your permission, for example, if 
it is requested by Congress. Information may also be released for certain research purposes with 
due consideration and protection, to those engaged by the agency for research purposes, to certain 
federal and state agencies, for HIV partner notification, for infectious disease or abuse or neglect 
reporting, to tumor registries, for quality assessment and medical audits, or when the NIH is 
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
13
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
involved in a lawsuit.  However, NIH will only release information from your medical record if it 
is permitted by both the Certificate of Confidentiality and the Privacy Act.
POLICY REGARDING RESEARCH-RELATED INJURIES  
The NIH Clinical Center will provide short-term medical care for any injury resulting from your 
participation in research here. In general, no long-term medical care or financial compensation for 
research-related injuries will be provided by the NIH, the NIH Clinical Center, or the Federal 
Government. However, you have the right to pursue legal remedy if you believe that your injury 
justifies such action.
PROBLEMS OR QUESTIONS
If you have any problems or questions about this study, or about your rights as a research 
participant, or about any research-related injury, contact the Principal Investigator, Alicia Widge, 
M.D., MS 
alicia.widge@nih.gov 301-761-7968. Other researchers you may call are: [Floreliz 
Mendoza, RN, at 301-451-8715. You may also call the NIH Clinical Center Patient Representative 
at 301-496-2626, or the NIH Office of IRB Operations at 301-402-3713, if you have a research-
related complaint or concern.
CONSENT DOCUMENT 
Please keep a copy of this document in case you want to read it again.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATION
Consent to Participate in a Clinical Research Study
NIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 04/20/2020
Page 
14
 of 
14
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Adult Research Participant: 
I have read the explanation about this study and have been given the opportunity 
to discuss it and to ask questions. I consent to participate in this study.
Signature of Research Participant
Print Name of Research Participant
Date
Witness to the oral short-form consent process only: 
This section is only required if you are doing the oral 
short-consent process and this English consent form has been approved by the IRB for use as the basis of 
translation.
Witness:
Signature of Witness
*
Print Name of Witness
Date
*NIH ADMINISTRATIVE SECTION TO BE COMPLETED REGARDING THE USE OF AN 
INTERPRETER:
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent and served as a witness.
 
The investigator obtaining consent may not 
also serve as the witness.
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent but did not serve as a witness. The name or ID code of the person 
providing interpretive support is:
.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (2)
Version Date: 04/20/2020
Page 
1
 of 
4
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
PRINCIPAL INVESTIGATOR:  Alicia Widge, MD, MS
STUDY TITLE:  VRC 321: A Phase I Open-Label Clinical Trial to Evaluate Dose, Safety, 
Tolerability, and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine, 
VRCFLUNPF099-00-VP, in Healthy Adults
STUDY SITE:  NIAID/VRC
Cohort: 
Healthy volunteer 
Supplementary Consent Version:  
3.0, April 20, 2020
WHO DO YOU CONTACT ABOUT THIS STUDY? 
Principal Investigator: Alicia Widge, MD, MS:
Study Coordinator: Floreliz Mendoza, RN;
Supplementary consent for extended genetic testing (optional)
You agreed to participate in VRC 321 study for testing of an investigational vaccine to prevent H1 
influenza (flu) virus infection. This additional consent covers optional genetic testing that you may 
agree to. If you do not agree to this additional testing, you still can participate in the VRC 321 
study.
There is a new type of genetic test that lets us look at the expressions of genes, called transcriptome 
sequencing. This test lets us look at the genes that are actively expressed at any given moment. 
However, it does not measure the amount of protein produced. Also, this new genetic test is still 
in development and researchers are working on understanding the data and how that data can be 
utilized in various clinical applications, such as in medicine to help prevent disease. 
This test may take a long time to understand, and we may not have any news to give you about it. 
Since we are looking for genes that control infection or immune response, we will not report to 
you or your doctors anything that we find that is not related to infection or immunity. However, if 
we find something in your DNA that we think is urgent to deal with because of your health, we 
will confirm the result and then tell you about it. We think this sort of problem will be very rare.
Genetic Data Sharing
Following genetic testing for transcriptome sequencing, your sequence data may be shared in a 
controlled access public database, for other investigators to benefit from it. However, no personal, 
identifiable information will be shared in this process, as the shared results will be coded with no 
link back to you.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (2)
Version Date: 04/20/2020
Page 
2
 of 
4
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Certificate of Confidentiality
To help us protect your privacy, the NIH Intramural Program has received a Certificate of 
Confidentiality (Certificate). With this certificate, researchers may not release or use data or 
information about you except in certain circumstances.  
NIH researchers must not share information that may identify you in any federal, state, or local 
civil, criminal, administrative, legislative, or other proceedings, for example, if requested by a 
court.  
The Certificate does not protect your information when it:  
1. is disclosed to people connected with the research, for example, information may be used 
for auditing or program evaluation internally by the NIH; or 
2. is required to be disclosed by Federal, State, or local laws, for example, when information 
must be disclosed to meet the legal requirements of the federal Food and Drug 
Administration (FDA); 
3. is for other research;
4. is disclosed with your consent. 
The Certificate does not prevent you from voluntarily releasing information about yourself or your 
involvement in this research. 
The Certificate will not be used to prevent disclosure to state or local authorities of harm to self or 
others including, for example, child abuse and neglect, and by signing below you consent to those 
disclosures. Other permissions for release may be made by signing NIH forms, such as the Notice 
and Acknowledgement of Information Practices consent.
Privacy Act
The Federal Privacy Act generally protects the confidentiality of your NIH medical information 
that we collect under the authority of the Public Health Service Act.  In some cases, the Privacy 
Act protections differ from the Certificate of Confidentiality.  For example, sometimes the Privacy 
Act allows release of information from your record without your permission, for example, if it is 
requested by Congress. Information may also be released for certain research purposes with due 
consideration and protection, to those engaged by the agency for research purposes, to certain 
federal and state agencies, for HIV partner notification, for infectious disease or abuse or neglect 
reporting,  to tumor registries, for quality assessment and medical audits, or when the NIH is 
involved in a lawsuit.  However, NIH will only release information from your medical record if it 
is permitted by both the Certificate of Confidentiality and the Privacy Act.
POLICY REGARDING RESEARCH-RELATED INJURIES  
The NIH Clinical Center will provide short-term medical care for any injury resulting from your 
participation in research here. In general, no long-term medical care or financial compensation for 
research-related injuries will be provided by the NIH, the NIH Clinical Center, or the Federal 
Government. However, you have the right to pursue legal remedy if you believe that your injury 
justifies such action.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (2)
Version Date: 04/20/2020
Page 
3
 of 
4
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
PROBLEMS OR QUESTIONS
If you have any problems or questions about this study, or about your rights as a research 
participant, or about any research-related injury, contact the Principal Investigator, Alicia Widge, 
M.D., MS alicia.widge@nih.gov  Another researcher you may call is: Floreliz 
Mendoza, RN, at   You may also call the NIH Clinical Center Patient Representative 
at 301-496-2626, or the NIH Office of IRB Operations at 301-402-3713, if you have a research-
related complaint or concern.
CONSENT DOCUMENT 
Please keep a copy of this document in case you want to read it again.
            1  0032
                   05/1 /2020
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (2)
Version Date: 04/20/2020
Page 
4
 of 
4
CC ICF template v. 09.27.19
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Adult Research Participant: 
I have read the explanation about this study and have been given the opportunity 
to discuss it and to ask questions. I consent to participate in this study.
Signature of Research Participant
Print Name of Research Participant
Date
Witness to the oral short-form consent process only: 
This section is only required if you are doing the oral 
short-consent process with a non-English speaking subject and this English consent form has been approved 
by the IRB for use as the basis of translation.
Witness:
Signature of Witness
*
Print Name of Witness
Date
*NIH ADMINISTRATIVE SECTION TO BE COMPLETED REGARDING THE USE OF AN 
INTERPRETER:
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent and served as a witness.
 
The investigator obtaining consent may not 
also serve as the witness.
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent but did not serve as a witness. The name or ID code of the person 
providing interpretive support is:
.
            1  0032
                   05/1 /2020